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ABSTRACT 
 
Imidazolium trans-[tetrachloro (dimethyl sulfoxide)(imidazole)ruthenate(III)], 
NAMI-A, is an experimental metastasis inhibitor whose specific mechanism of 
activation and action remains to be elucidated. In the nucleophilic and reducing 
physiological environment; it is anticipated that the most relevant and available 
reductants upon introduction of NAMI-A as a therapeutic agent will be the biologically-
relevant free thiols. The kinetics and mechanisms of interaction of NAMI-A with 
biologically-active thiols cysteamine, glutathione, cysteine and a popular 
chemoprotectant, 2-mercaptoethane sulfonate (MESNA) have been studied 
spectrophotometrically under physiologically-relevant conditions. 
The reactions are characterized by initial reduction of NAMI-A with 
simultaneous formation of dimeric thiol and subsequent ligand exchange with water to 
various degrees as evidenced by Electospray Ionization Mass Spectrometry. 
Stoichiometry of reactions shows that one molecule of NAMI-A reacted with one mole 
of thiol to form corresponding disulfide cystamine, dimeric MESNA, oxidized 
glutathione and cystine. Observed rate constants, ko, for the reaction of NAMI-A with 
cysteamine, MESNA, GSH and cysteine were deduced to be 6.85 + 0.3 x 10-1, 9.4 + 0.5 
x 10-2 , 7.42 + 0.4 x 10-3  and 3.63 + 0.3 x 10-2 s-1 respectively.  
Activation parameters determined from Arrhenius plots are indicative of 
formation of associative intermediates prior to formation of products. A negative 
correlation was obtained from the Brønsted plot derived from observed rate constants 
ii 
 
and the pKa of the different thiols demonstrating significant contribution of thiolate 
species towards the rate. In conclusion, interactions of NAMI-A with biologically-
active thiols are kinetically and thermodynamically favored and should play significant 
roles in in vivo metabolism of NAMI-A. 
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CHAPTER ONE 
1.0 Introduction 
1.1 Metals in nature 
The existence and importance of metal ions in the physiological system is well 
established.1-3 Nature utilizes metal ions for functions such as oxygen transport, 
synthesis of vitamin A, fatty acids and cholesterol; formation of urea, detoxification, 
bone development, and normal functioning of the nervous system.4-8 Transition metal 
ions are of particular interest because, even though they occur in trace amounts, their 
excess or deficiency may result in deleterious conditions such as anemia,2 liver and 
oxidative damage, among others.3;9 Iron, for instance, supports fundamental biological 
functions involved in the handling and transport of oxygen, detoxification and synthesis 
of DNA,10 but is potentially toxic to cells.11-13 It has been implicated in events that lead 
to liver and heart diseases,14  neurodegenerative disorders,15 diabetes,2 cancer16and 
catalytic production of free radicals.9 Transition metals are mostly found complexed in 
the active sites of metalloenzymes such as nickel in urease17 or iron in tyrosine 
hydroxylase, carbonic anhydrase dioxygenases, and isopenicillin N-synthase.18  
Today there is increased understanding of the activities of transition metal ions 
and complexes in biological systems.19 Enlightenment in areas such as metalloprotein 
functions, models of metal ion active sites, how metal ions are delivered to the active 
sites,20;21 and involvement of  transition metals in some disease states22,23 have 
stimulated the use of metal ions and complexes for therapeutic strategies. One area of 
global application of metal-based therapeutics is in the treatment of cancer.24 
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1.2 Cancer and cancer statistics 
 According to the American Cancer Society, cancer is a group of diseases 
characterized by uncontrolled growth and spread of abnormal cells that result from 
sequential acquisition of mutations in genes that control cell growth, differentiation, and 
death.25 A recent report from Centers for Disease Control and Prevention’s National 
Center for Health Statistics names cancer as the second leading cause of death in the 
United States, solely accounting for 559,888 (23%) of the 2.42 million total registered 
deaths in 2006.26 It is second only to heart disease which accounts for twenty six 
percent of registered deaths.26;27 Although overall cancer incidence rates have been on 
the decline,  1,638,910 new cases and 577,190 cancer deaths are predicted to occur in 
2012.28;29 Considerable treatment success has been achieved with the use of transition 
metal complexes, especially in the case of testicular cancer with the use of cis-
diamminedichloroplatinum(II) (Cisplatin).30 The structure is shown in Figure 1.  
Cisplatin is able to damage DNA by binding to N-7 of adjacent guanosine residues 
which effects distortions that make DNA function and repair impossible.31 Cisplatin has 
up to a 90% cure rate for testicular cancer and, in combination with other drugs, has a 
very high activity against ovarian, cervical and bladder carcinomas.32-35 
 
 
                                                       
Figure 1-1: cis-diamminedichloroplatinum(II), (Cisplatin) 
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This success is, however, marred by neurotoxicity, nephrotoxicity, alopecia and a lack 
of selectivity towards cancer cells.36;37 Drug resistance, metastasis and activity over a 
small range of cancer types are other limiting factors. Analogues of cisplatin, two of 
which are shown in Figures 1.2a-b, have been synthesized, in an effort to circumvent 
the aforementioned problems. These complexes are also in clinical use38 and have 
demonstrated similar mechanism of action to that of Cisplatin.39  
 
                                                                                  
(a)        (b)  
Figure 1-2: (a) cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II),  
(Carboplatin) 
       (b) cis-Diammine(glycolato)platinum(II), (Nedaplatin) 
  
Carboplatin and Nedaplatin are less toxic. Cisplatin and its analogues, however, 
are almost inactive against several malignancies with high incidence rates such as colon 
and rectum, lung, breast and prostate carcinomas.40-43 Also, a commonly occurring side 
effect of platinum anticancer drugs is ototoxicity.44 Reports have indicated elevation of 
hearing threshold in greater than 50% of patients treated with cisplatin,45 and 84% of 
children treated with both cisplatin and carboplatin experience hearing loss.44 Otoxicity 
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has been labeled as a commonly occurring toxicity that may influence academic and 
social development.44  
1.3 Metastasis 
Metastasis describes the ability of cancer cells to penetrate into lymphatic and 
blood vessels, circulate through the bloodstream, and then invade normal tissues 
elsewhere in the body. Metastasis, rather than primary tumor, is the major cause of 
death for cancer patients with solid tumors.46 This is reflected by 5-year-survival rates 
which are higher than 90% for patients in early stages, which drop to 65% for patients 
initially diagnosed with regional lymph node metastases and is further reduced to less 
than 10% in patients with distant metastases.47-49 Metastasis involves a series of events 
through which cancer cells separate from the parent tumor and enter the circulatory 
system, float elsewhere, continue proliferation and form a secondary locus of tumor.50 
This process is grossly inefficient in that only few of millions of cells released into 
circulation are able to colonize a secondary site.51;52 Alarming failure rate of the process 
might be due to hostility of normal healthy tissues.53 Metastatic cells acquire 
characteristics making them adaptable to their new microenvironment: these 
characteristics differentiate them from the primary tumor and consequently present 
differing chemical sensitivity to cytotoxic agents.54-57 Figure 1-3 highlights the 
selectivity of metastatic cells for their preferred site for colonization in comparison to 
primary tumor. Tumor cells can survive in their new microenvironment only if they 
meet certain cellular preconditions which explain organ-specific metastatic behavior.50  
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These cells flourish in new tissue habitats and ultimately cause organ dysfunction and 
death. No effective therapeutic option is currently available for metastasis,58 neither is 
there an anticancer drug with activity over a wide range of cancer and metastasis. 
Hence, the intense research efforts towards finding therapeutics of a more desirable 
profile.   
 
Figure 1-3: Organ specific colonization demonstrated by metastatic cells. Secondary 
organs place certain demands on invading tumor cells.50  
 
1.4 Anticancer prodrugs 
Prodrugs are chemicals with little or no pharmacological activity before 
undergoing biotransformation to a therapeutically active metabolite.59 In drug research 
and development, several possible improvements on the pharmacological profile of a 
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drug may be achieved by exploring the prodrug concept. Several improvements have 
been achieved with this concept. Figure 1-4 summarizes the possible effects.  
 
      
Figure 1-4: Classification of prodrug research objectives. [Adapted from Testa, B.  
2009. 59] 
 
 Several non-platinum transition metal complexes have been synthesized for 
possible reduction or elimination of the undesired effects associated with platinum 
anticancer drugs presently in clinical use.60-65 Of special interest are ruthenium 
complexes that have shown activity against platinum resistant cancer cell lines, 
colorectal cancer and metastasis Figure 1.5(a-d).58 Indazolium trans-bis(indazole)- 
tetrachlororuthenate(III), IndICR, is active against colon carcinomas and a variety of 
primary explanted human tumors.66;67 It is noteworthy that 83% of patients with solid 
tumors who were treated with IndICR present stable disease.68 Sodium trans-
[tetrachloro (dimethyl sulfoxide)(imidazole) ruthenate(III)], called by the acronym 
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NAMI (Figure 1-5c) also shows low host toxicity in active doses.69;70 The observed 
reactivities of these complexes can be considered peculiar since ruthenium to date has 
no known biological function. 
    
    (a) NAMI-A          (b) ICR 
 
      
       (c) NAMI          (d) IndICR 
Figure 1-5: Ruthenium anticancer prodrugs 
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1.5 Antitumor Metastasis Inhibitor 
 Imidazolium trans-[tetrachloro (dimethyl sulfoxide)(imidazole)ruthenate(III)], 
NAMI-A (Figure 1-5 a), is a ruthenium complex that shows low host toxicity with 
marked efficacy against metastases.70-72  It has successfully completed phase I of clinical 
trials and is currently undergoing phase II studies.73 Results of Phase I and 
pharmacological study of this prodrug demonstrate no severe side effect (formal 
common toxicity criteria (CTC) grade 3) was developed from its use. Formation of 
painful blister was considered dose limiting.73 NAMI-A has demonstrated up to 100 % 
metastasis reduction on preclinical models of solid metastasizing tumors such as Lewis 
lung carcinoma, TS/A mammary adenocarcinoma,72 MCa mammary carcinoma,74 B16 
melanoma,75 and up to 90 % on H460M2 human NSCLC xenograft.74;76  
One of the initial stages in metastasis progression is reduction of cell adherence 
leading to detachment from a primary site,50 NAMI-A has been found to increase cell 
adherence thereby interfering with other processes leading to full colonization.76-78 
NAMI-A has very high selectivity towards metastases while still having some effect on 
the primary tumor. Figure 1-6 illustrates the effect of NAMI-A.79 NAMI-A has been 
shown to be effective, irrespective of the origin or the stage of growth of metastasis.72 A 
critical observation of Figure 1-6 also reveals the inconsequential effect of NAMI-A on 
primary tumor.  
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Figure 1-6: Selective metastatic removal by NAMI-A. It shows weak reduction of 
primary tumor while removing close to 100% of metastatic cells.79 
 
Cancer cells are constantly proliferating and an important characteristic of tumor 
growth is the doubling time. Usually a tumor is undetected until it has doubled 30 times 
(109 cells). A tumor mass is sufficient to kill its host after 35 doublings which 
corresponds to 1012 cells.80 Figure 1-7 illustrates the relationship between tumor cell 
count, number of doublings and tumor detection. This indicates that a significant 
portion of tumor growth is completed by the time of detection, although, methods such 
as ultrasonography and Magnetic Resonance Imaging offers detection of tumors less 
than 1 cm.81 A chemotherapy regimen that focuses solely on elimination of metastasis 
will spare the primary tumor which continues its growth cycle normally. It is then 
rational to suggest that a regimen that will maximize NAMI-A to full potential should 
contain another anticancer drug that is effective towards primary tumor. 
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Figure 1-7: Hypothetical tumor growth curve.80  
 
Research efforts directed at understanding the mechanism of action of  NAMI-A are 
still in their infancy, with recent efforts focused on finding the effects of chemical 
stability, photostability, interaction with human serum albumi and comparison of 
treatment outcomes employing different routes of application, among others.79;82-86 
 
1.6 Activation by reduction hypothesis 
Transition metal complexes readily undergo ligand substitution and redox 
reactions. The roles of these reactions and the biological activity of a metal complex 
depend both on thermodynamics and kinetics. Activation by reduction has been 
proposed for this prodrug, NAMI-A, 33;82;87;88 which may be a factor in its preferential 
toxicity towards hypoxic tumor and metastatic cancer cells.33 In support of this 
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“activation-by-reduction” hypothesis, ligand exchange and antimetastatic activity of 
NAMI-A is enhanced upon addition of biological reductants such as ascorbic acid, 
cysteine, or glutathione.84;89 
 The major difference between solid tumors and healthy tissues is the nutritional 
and metabolic environment. The vasculature of tumors is often inadequate to supply the 
nutritional needs of constantly growing tumor cells leading to oxygen deficiency 
(hypoxia). Tumor cells produce lactic acid due to their high dependence on aerobic 
glycolysis, resulting in low pH.90 Low pH environment and low oxygen favor reduction 
and this contributes towards the specificity of reduction-activated prodrugs. Ruthenium 
is able to mimic iron by binding to certain biological molecules such as serum 
transferrin and albumin since ruthenium and iron are in the same group.91 Transferrin 
and albumin are proteins used by mammals to solubilise and transport iron, thereby 
reducing its toxicity. Preferential selective delivery of the prodrug to tumor cells by 
transferrin transport has been suggested.91 Rapidly dividing cancer cells have higher 
demand for iron and thus have an increased number of transferrin receptors compared to 
normal cells, resulting in selective deposition of the prodrug.85;92 Figure 1-8 illustrates 
the low host toxicity of the ruthenium complex. Binding of NAMI-A to albumin and 
tranferrin were reported not to be particularly beneficial for antimetastatic activity 
although may extends biological half life.93 
Ruthenium complexes in the +3 state are kinetically inert compared to the +2 
complexes. This kinetic inertness offers an advantage in that the prodrug gets to its 
target before transformation or activity. Electrons needed for this reduction are 
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physiologically accessible and may be provided by biological reductants such as 
glutathione, ascorbic acid and cysteine residue of proteins.94  
 
 
  Figure 1-8: Selective uptake of ruthenium loaded transferrin by cancer cells.92  
 
1.7 Thiols 
 Thiols are sulfhydryl compounds. The presence of thiol functionality in 
compounds makes them susceptible to various transformations due to wide range of 
accessible oxidation states of sulfur, -2 to +6. Endogenous thiols include glutathione 
(GSH), cysteine, cysteamine and homocysteine. GSH, a tripeptide, is the most abundant 
and occurs in virtually all mammalian cells.95 Thiols are involved in many redox 
processes especially in maintaining the intracellular redox state through thiol-disulfide 
exchange.96 Extracellular cysteine/cystine redox status has been implicated in cell 
Transferrin receptor
Ruthenium loaded transferrin
Cancer cell Healthy cell
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growth and apoptosis.97 Also, inadequate sulfur amino acid intake results in oxidized 
thiol/disulfide redox status which is associated with oxidative stress and onset or 
progression of diseases.98;99 An interesting illustration of the importance of redox status 
is that the reduction potential of a cell with 1.0 mM intracellular GSH concentration 
changes from -250 mV to -190 mV if 18 µM of the GSH is oxidized.97 This change in 
reduction potential is adequate to change the functional state of the cell from 
proliferation (multiplication of epithelial cells) to differentiation (specialization or 
maturation).97;100-103 Involvement of thiols in several important cell functions makes it 
impossible to exclude their interaction with most drugs in establishing a detailed 
mechanism of drug biotransformation and action.  
There are biologically-active thiols that may be introduced as pharmaceuticals. 
For example, N-acetyl cysteine is used as an adjuvant in respiratory conditions with 
excessive mucus production and has been shown to prevent metastasis in animal 
models.104 Sodium-2-mercaptoethanesulfonate, MESNA, prevents 
ischemia/reperfusion-induced renal damage, and is also used as a detoxifying agent to 
inhibit the hemorrhagic cystitis induced by chemotherapy drugs.105-109  2-
mercaptopropionyl glycine, also known as thiopronin, prevents hepatotoxicity of 
Isoniazid used in tuberculosis treatment by inhibiting and scavenging free radicals.110  It 
reduces cisplatin-induced nephrotoxicity111 and is also used in treatment of rheumatoid 
arthritis and cystinuria.112;113 Thiol protection may not necessarily be desirable in some 
cases since this may result in drug resistance as observed in reduced anticancer activity 
of cisplatin in the presence of homocysteine and N-acetyl cysteine.114 It has been 
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reported that a possible pathway for regulation of human immunodeficiency virus 
1(HIV-1) protease activity involves modification of the cysteine residue of HIV-1.115 
  
The highly nucleophilic sulfur center is critical to the functioning of thiol-based 
drugs as radioprotective agents and in DNA repair. The chemistry involved in DNA 
repair by thiols is represented by R 1.1 – R 1.4.116  
 
DNA   + RSH                    DNA  +  RS   +  H+
DNA   + RS-                      DNA  +  RS
+   RSH RSSR    +   H+
RSSR    +  DNA DNA  +  RSSR
R1.1
R1.2
R1.3
R1.4
RS
 
 
1.7.1 Thiol oxidation 
Most biological processes involving the thiol moiety occur through oxidation, 
some of which were mentioned earlier.97;117 Non-radical oxidants of potential relevance 
to oxidative stress include H2O2, HOCl and ONOOH,118-120 and these can react with 
cysteine or methionine residues of proteins. Oxidation of thiols may proceed through a 
variety of pathways resulting in series of different metabolites and products.121-125 
Studies from our lab have demonstrated exotic dynamics in oxidation of low molecular 
weight organosulfur compounds involving some of these oxidants.126-130 Scheme 1-1 
shows possible oxidation pathways for a thiol ranging from a one electron oxidation to 
disulfide all the way to eight-electron oxidation to form sulfate.  
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Scheme 1-1: Possible oxidation pathways for a thiol127 
 
 Enzymatic oxidation of thiols by peroxidase; mainly by horseradish peroxidase, 
lactoperoxidase, and myeloperoxidase, have been shown to yield thiyl radicals131;132. 
Thiols can also be oxidized to disulfide by metal ions or complexes. This oxidation 
generally proceeds through thiyl radical formation (R1.5 and 1.6). Once formed, the 
thiyl radical can undergo several other reactions depending on what species are 
immediately available. Two thiyl radical molecules can react to form the disulfide 
(R1.6), a thiyl radical can react with the parent thiol (R1.7) or thiolate anion (R1.8) to 
form disulfide radical anion.133-135 Thiyl radicals have also been shown to form sulfenic 
acid and other oxygen containing products.133;135;136  
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RSH        +    Mn                           RS.   +    Mn-1     +    H+                              R1.5     
RS.          +    RS.                          RSSR                                                         R1.6
RS.          +    RSH                        RSSR.-    +     H+                                       R1.7
RS.          +    RS-                         RSSR.-                                                       R1.8
RSSR.-   +    Mn                           RSSR      +    Mn-1                                    R1.9
RS.   +    Mn     +    H2O                      RSOH
     
+    Mn-1    +     H+            R1.10
 
Scheme 1-2: Reactions involved in thiol oxidation by a metal ion or complex.133-135 
 
1.7.2 Metal binding 
Thiols can form complexes with metals ions or transition metal complexes 
where the sulfur atom of the SH group acts as the binding site.137;138 For instance, D-
penicillamine has been shown to form variable complexes; a purple paramagnetic 
complex and a yellow diamagnetic complex with copper; depending on the ratio of 
copper to penicillamine.139 The ability of thiols to form complexes with metals is being 
utilized in medicine for treatment of diseases involving excess metals in the 
physiological environment such as Alzheimer’s, Parkinson’s and Huntington’s 
diseases.140 Thiols can effectively remove excess metal by competing for the metal ion 
with biological binding sites. This type of treatment requires selectivity of the thiol 
towards certain metals in order to avoid possible depletion of essential metals. D-
penicillamine, a disubstituted cysteine, chelates excess copper and enhances copper 
excretion in Wilson’s disease.141;142 A process involving thiol-disulfide exchange in zinc 
fingers has been used to release complexed zinc. This process has been found to inhibit 
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both laboratory strains and clinical isolates of HIV-1.143-145 Dimercaptosuccinic acid 
and dimercaptopropionic sulfonate have gained general acceptance in the management 
of many human metal intoxications which include lead, arsenic, and mercury 
compounds.146-150 Metal binding properties of thiols have also been explored in 
modulating the functions of proteins containing the thiol moiety.151  
 In platinum cancer therapy, the metal binding characteristic of thiols may be 
beneficial152 but more often is undesirable since this interaction leads to reduced 
availability and deactivation of the platinum complex.153 Reports have shown this to 
play a significant role in drug resistance and inactivation153-157 Scheme 1-3 describes 
interactions of cisplatin with L-cysteine that results in its unavailability for its desired 
function.153;158 
It is interesting that interactions of NAMI-A with biological reductants such as 
thiols have been proposed to play a significant role in its activation as opposed to 
deactivation in the case of platinum drugs.153;158 It has also been shown that NAMI-A is 
rapidly reduced under physiological conditions94 with ambiguity as to whether its 
reduced form or hydrolytic derivative react with human serum albumin and ascorbic 
acid in acidic medium.159 There have been several reports of hydrolysis pathways for 
the promising prodrug,160;161 the mechanism of action and the nature of chemical 
species responsible for the pharmacological properties of this prodrug are yet to be 
unraveled and kinetics studies directed at elucidating the mechanism of its interaction 
with biologically-relevant thiols is simply nonexistent.  
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Scheme 1-3: Reactions between cisplatin and L-cysteine at neutral pH153;158 
Legend: Cys – Cysteine, Cl- - Chloride ion 
 
1.8 This Study 
Metastases, due to their inadequate responsiveness towards any clinically 
available cancer drug heighten the need for drugs that are effective against metastases. 
Development of NAMI-A, a compound that is 1,053 times less toxic than cisplatin, 162 
is a step towards achieving the long desired activity against metastasis. Reports have 
excluded DNA binding as the major target for antimetastatic activity of NAMI-A163-165 
suggesting that its interaction with biomolecules other than nucleobases may represent 
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the molecular basis for its peculiar biological activity. An understanding of the chemical 
transformations of NAMI-A upon interaction with endogenous molecules and 
xenobiotics is of prime importance for its pharmaceutical and biomedical applications.  
Absorption, distribution, metabolism, excretion and toxicity (ADMET) are 
important concepts in drug therapy and depend on kinetics and thermodynamics of 
interactions of the drug with biomolecules. Even after 40 years of clinical use of 
Cisplatin (world’s most widely used anticancer drug), the mechanism of action of the 
drug is yet to be completely unraveled.166 Recognizing this fact and understanding that 
interaction of NAMI-A with xenobiotics are of potential biological importance, the 
work reported in this dissertation therefore focused on: 
(1) Investigating molecular transformations involved in the interactions of NAMI-A 
with select thiols (GSH, cysteine, cysteamine and MESNA) and identification of 
observable species. The choice of these thiols examines reactions of NAMI-A 
with cellular thiols and clinical chemoprotectant, MESNA, while providing a 
model for NAMI-A interaction with proteins and enzymes with thiol residues.  
(2) Studying and determining the kinetics and thermodynamics of these interactions.  
(3) Deduction of plausible mechanism of interaction from experimental results. 
Plausible reaction mechanisms will be proposed for the studied reactions based 
on experimental results obtained.  
This is information necessary for any xenobiotic, especially an experimental drug with a 
desirable pharmacological profile whose cellular target remains to be determined. An 
understanding of these interactions on a molecular level may give access to control of 
20 
 
drug activity, refinement of structures for more desirable effects and, most importantly, 
ensure that treatment/drug metabolism proceeds in a predictable manner.  
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CHAPTER TWO 
2.0 Instrumentation, Materials and Methods 
2.1 Introduction 
Kinetics deal with the study of reaction rates in an effort to understand the 
quantities that influence the rates, describe the series of elementary steps involved in 
reaction systems (the mechanism) and deduce rate parameters governing such reactions. 
Knowledge of reaction rates has many practical applications including, but not limited 
to, designing an industrial process, understanding complex dynamics of the atmosphere, 
optimizing synthetic processes, establishing the best administration mode for a drug, 
deducing metabolic pathways and improving specificity of therapeutics. Kinetics can 
also be employed in establishing indices responsible for drug resistance and elucidating 
pathways to such drug resistance. In order to achieve these applications, reaction 
dynamics require a series of information on the progress of reaction. The necessary 
information includes dynamical variables such as temperature, pressure, pH, reactant 
concentrations, solvent and ionic strength.  
The reaction to be studied dictates the set of conditions required. Careful choice 
of analytical techniques and instrumentation, therefore, is required for reliable kinetic 
outcomes. The stoichiometry of reaction is the first step in establishing an overall 
equation for a reaction. Specialized analytical methods such as nuclear magnetic 
resonance spectroscopy, electron paramagnetic resonance spectroscopy, infrared and 
Raman spectroscopy, ultraviolet and visible spectrophotometry, mass spectrometry, 
stopped flow spectrophotometry, etc. are tools used for monitoring reaction progress via 
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determination of reactants or intermediate concentrations as well as product 
identification. 
 
2.2 Instrumentation 
2.2.1 Conventional UV/Vis Spectrophotometry 
UV-visible spectroscopy measures absorption of the electromagnetic radiation 
caused by electronic transitions from the ground state to the excited state of bonding 
and non-bonding electrons of ions or molecules. For this study, a Perkin-Elmer Lambda 
25 UV-VIS spectrophotometer featuring a double beam, all-reflecting system with a 
spectral range of 200 nm to 700 nm was used. For this instrument, the visible region 
uses a halogen lamp and the UV region uses a deuterium lamp.167 The 
spectrophotometer is interfaced to a computer with Perkin-Elmer UV WinLab 
software167 for data acquisition, storage and analyses. The instrument is attached to a 
thermostated water bath for maintenance of constant temperature. Spectral changes of 
reaction mixtures were recorded over the wavelength range to establish suitable 
wavelength for kinetics observations. 
 
2.2.2 Stopped-flow Spectrophotometry 
 Stopped-flow spectrophotometry has the advantage of using small amounts of 
reactants, and providing rapid and efficient mixing that comes with an analytical 
response that has good time resolution. It allows for changes in optical properties of 
solutions (in this case absorbance) to be monitored using UV-VIS detection. It offers an 
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advantage in the study of fast reactions which might have been impossible with 
conventional UV/Vis spectrophotometric techniques. A Hi-Tech Scientific SF61-DX2 
double mixing stopped-flow spectrophotometer was used for all kinetic studies. 
Amplification and digitization of detector signal from the spectrophotometer was done 
via an Omega Engineering DAS-50/1 16-bit A/D board interfaced to a computer for 
storage and data analysis. A dead time of 1.0 ms will ensure observation of the crucial 
initial parts of rapid and even complex reactions which otherwise might have been 
impossible. The light source is a 75W super quiet Xenon arc lamp. Figure 2.1 is a 
schematic diagram for the sample handling unit that separates compartments for up to 
three reactants allowing for different mixing sequences in optimizing experiment 
procedure.  
 The double mixing mode enables transient species formed by mixing reactants 
in A and B to be subsequently mixed with a third reactant, C, after a delay period if 
needed (refer to Figure 2-1). Reactant reservoir D can be reserved for the buffer and this 
pushes the premixed solutions A and B (from mixer 1) to a second mixer (mixer 2) 
where it reacts further with reactant C. The resultant mixture passes through a 
measurement flow cell and into a stopping syringe where the flow is stopped. Just prior 
to stopping, a steady state flow is achieved. 
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Figure 2-1: Sample Handling Unit (SHU) flow circuit diagram for the SF-61DX2 Hi-
Tech KinetAsyst stopped-flow spectrometer. [Courtesy of Hi-Tech Scientific operator’s 
Manual] 
 
2.2.3 Electrospray-Ionization Mass Spectrometry (ESI-MS):  
 Mass spectrometry, MS, is an analytical technique that sorts and measures 
ionized molecules based on their mass-to-charge ratios. The possibility of observing the 
fragmentation pattern of a molecule makes MS an invaluable technique for structural 
elucidation. This spectrometric method works on the basic principle of separation of 
ions of a compound on the basis of their mass-to-charge ratio (m/z) and the number of 
ions representing each m/z unit when a compound is ionized. Ionization method is 
dictated by the nature of analyte.  Electrospray ionization method which has the 
advantage possible molecular determination of intact analytes is a method of choice.  
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 Figure 2-2 describes the mechanism of ion formation using ESI. An analyte, 
usually dissolved in a polar volatile solvent, is introduced and passes through the 
electrospray needle to which a high potential difference has been applied (typically 2.5 
to 4 kV). This potential difference forces the spraying of droplets with a surface charge 
of the same polarity as the needle. Solvent evaporation occurs as the charged droplets 
are repelled towards the counter electrode (shown in blue). The rapid shrinking of the 
droplets by evaporation of solvent increased charge density on their surface, a critical 
point (Rayleigh Stability limit) is reached when the charge density of the droplet and the 
attraction of the positive ions to the counter electrode overcomes the surface tension 
holding the droplet together, leading to fission (coulombic explosion) with the release 
of smaller droplets containing charged analyte molecules.168;169  
 
 
Figure 2-2: Schematic for ion formation in ESI.170  
Spray needle tip
Taylor 
cone
Cone 
(counter electrode)
analyte 
molecule
multiply 
charged droplet 
“Coulombic”
explosion
multiply 
charged droplet 
analyte 
ions
the ‘Rayleigh” 
limit is reached
solvent
evaporation
26 
 
The mass spectral analysis for product identification in this study was performed 
using a Thermo LTQ Orbitrap Discovery hybrid mass spectrometer (San Jose, CA), 
equipped with an Ion Max ESI source. This combines a soft ionization technique, large 
mass range of (50 - 2000 m/z), mass accuracy of <2 ppm root mean square (r.m.s) and 
up to 30,000 resolving power with a detect time of 400 ms.171;172 (LTQ Orbitrap 
Discovery Hardware Manual 1-5 ThermoFisher Scientific) 
 
2.2.4 Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear Magnetic Resonance spectroscopy is an essential analytical tool used in 
chemical analysis and fundamental research. Its versatility derives from the atomic 
nature of the information it provides. In principle, nuclei that contain odd mass numbers 
(such as 1H, 13C, 19F, and 31P) or odd atomic number (such as 14N and 2H) absorb 
electromagnetic radiation at a frequency characteristic of the nuclei in the presence of 
an external magnetic field.173 The signal in NMR spectroscopy is due to the disparities 
in the energy absorbed by the nuclei as they are excited from the lower energy state to 
the higher energy state, and the energy emitted by the nuclei as they relax from the 
higher energy state to the lower energy state. The NMR technique was used in this 
study for confirming the structure of NAMI-A, where a comparison was made to 
literature. 
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2.2.5 Electron Paramagnetic Resonance Spectroscopy (EPR) 
EPR is a technique for measuring absorption of electromagnetic radiation by an 
electron spin system.173 EPR has evolved to be a nondestructive, noninvasive analytical 
technique for structural and dynamical information. It has very high sensitivity with a 
detection limit in the nanomolar range. EPR has been applied in the measurement of 
both in vitro and in vivo free radical intermediates from drugs and oxidative processes. 
Pharmacokinetic information of paramagnetic compounds in mice have been obtained 
in mice just by placing the tail of the animal directly in the EPR resonator.174 EPR has 
proven useful in evaluation of oxidative stability of vegetable oils.175  
Free radicals have been implicated in metabolism of sulfhydryl moieties 
especially in oxidative disease states.176 Since reactions in this study involve electron 
transfer, the possibility therefore arises for involvement of free radical mechanisms. 
EPR measurements were carried out for detection and possible quantification of free 
radicals on a Bruker™ Biospin e-scan spectrometer designed to perform EPR 
measurements in the X-band-range. However, our reactions did not demonstrate 
involvement of free radicals as indicated by EPR silent reaction solutions in the 
presence of DMPO spin trap. This gave an indication that at least, non-metal centered 
radical (sulfur, oxygen or carbon) were not involved, since the 300G sweep width of our 
instrument is not sufficient for a most metal based radicals. 
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2.3 Materials 
  Glutathione, cysteamine, L-cysteine, 2-mercaptoethane sulfonate (MESNA), 
sodium hydroxide, sodium chloride, sodium perchlorate, perchloric acid, absolute 
ethanol, acetone, diethyl ether, hydrochloric acid, imidazole, dimethyl sulfoxide, 
deuterium chloride, deuterium oxide (all from Sigma-Aldrich), monosodium phosphate, 
monohydrate, disodium phosphate heptahydrate (from Fisher Scientific)  and ruthenium 
chloride  (from GFS chemicals) were of analytical grade and used as obtained. Aqueous 
solutions of reactants and buffers were prepared in distilled deionized water obtained 
from a Barnstead Sybron Corporation water purification unit that dispenses water with 
resistance of at least 18MΩ. 
pH of the solutions was measured with a 720 A+, Thermo Orion pH meter. 
Phosphate or acetate buffer was used to adjust the pH of the experimental solutions. 
Reactions were carried out at 25.0 ± 0.1°C (except for when isolating the effect of 
temperature) and at a constant ionic strength of 1.0 M using NaClO4 or NaCl (except 
when isolating the effect of ionic strength).  
 
2.4 Experimental Methods 
2.4.1 Synthesis of hydrogen trans-bis(dimethyl sulfoxide)tetrachlororuthenate- 
(III)  
NAMI-A precursor, Hydrogen trans-Bis(dimethyl sulfoxide) tetrachloro- 
ruthenate(III), was synthesized using published method.177 Briefly, 1.0 g of RuCl3.3H2O 
was dissolved in 30 mL of ethanol and refluxed for 3 hours. The filtered solution was 
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concentrated to about 3 mL and a mixture of 1 mL of 37 % HCl and 2 mL of DMSO 
was added. The resulting solution was kept at 80 oC for 15 minutes and a bright orange 
solution was obtained. The solution was cooled to room temperature and a 10 mL 
aliquot of acetone was added and then four drops of ethyl ether. Crystals were filtered, 
washed with cold acetone and ethyl ether and dried in a desiccator. The obtained 
crystals were characterized using X-ray crystallography using a Siemens P4 
diffractometer equipped with a graphite monochromator, a monocap collimator, a Mo 
Kα radiation source (λ = 0.71073 Å), and a SMART CCD detector.  
 
2.4.2 Synthesis of NAMI-A: NAMI-A was synthesized from this precursor.8  0.49 g 
of imidazole was added to 1.0 g of precursor suspended in 20 mL of acetone at room 
temperature. This mixture was stirred for 4 hours. The precipitate obtained in this 
manner was washed with cold acetone and ethyl ether. Characterization of this complex 
was done using FTIR, UV/VIS, NMR and electrospray ionization mass spectrometry 
(ESI-MS). Spectral data are in good agreement with those reported in the literature.178 
 Stock solution of NAMI-A was freshly prepared for each experiment. 
Proctection from light was not necessary due to reported evidence of photostability of 
NAMI-A solutions179and more importantly, it maintained pharmacological efficacy 
even after aging up to 8 hours.84  
 
2.4.3 Stoichiometric Determinations: Different ratios of NAMI-A to thiol 
concentrations were prepared from freshly prepared stock solutions vis: 0.25 to 4. 
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Residual absorbance at 390 nm of the solutions were measured and plotted against 
corresponding oxidant to reductant ratio. The stoichiometry was obtained as the ratio 
beyond which no more NAMI-A was consumed.  
 
2.4.4 Product Identification: Possible detection and identification of intermediates 
and product would be performed utilizing UV/VIS, NMR, ESI-MS or EPR techniques 
as the reactions require. For ESI-MS, aqueous reactant solutions were prepared in 
distilled deionized water with resistance of at least 18MΩ. 
 
2.4.5 Reaction Dynamics: Kinetics measurements were performed on the Hi-Tech 
Scientific single mixing (SF-61SX2) and double mixing (SF-61DX2) models stopped-
flow spectrophotometers. Stock solutions of thiols and metal complexes were freshly 
prepared for each set of experiments. The biologically-active thiols used in this work 
lack distinct absorption in the 200 – 700 nm region. This necessitated monitoring of 
reaction progress at the absorption wavelength of NAMI-A which has a distinct 
absorption in the visible region, λmax 390 nm. All kinetics experiments were carried out 
at 25.0 ± 0.1 °C except when the effect of temperature was monitored, in which case 
temperature range was 10 oC - 37 oC. A constant ionic strength of 1.0 M was maintained 
using sodium chloride or sodium perchlorate except when the effect of ionic strength 
was explored. For evaluation of reaction dependence on ionic strength, kinetics of 
reactions were examined using varying amounts of NaClO4. Contributions from all 
charged species (buffer, NAMI-A and sometimes the thiol) present in solution were 
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taken into consideration for these measurements using the standard calculation for ionic 
strength. 
 To evaluate effect of oxygen, argon was bubbled into freshly prepared solutions, 
and since reaction rate and profile did not change significantly from reactions run in 
ambient air. Similar results have been reported for the reaction of Indazolium trans-
bis(indazole)tetrachlororuthenate(III) with glutathione.180 All reactions were as such run 
in ambient air. In an attempt to simulate the physiological environment, experiments 
were carried out using bicarbornate buffer. The results, however, demonstrated that the 
pH was not adequately maintained. Phosphate buffer was therefore used to maintain a 
pH of 7.4. For reactions of NAMI-A with MESNA, reaction profile was monitored at 
four other pHs: 3, 4, 5, 6. Phase I clinical trials reported that NAMI-A can be safely 
administered at 300 mg/m2/day for 5 days every 3 weeks,181 corresponding to 6.55 x 10-
4
 mol/m2/day, therefore, < 1.50 x 10-4 M of NAMI-A was used. Pseudo-first-order 
condition of excess thiol was adhered to. 
 Chloride is found in most body fluids, including blood, plasma, serum, urine 
and saliva. Plasma chloride concentrations approximate to 100 mM in normal human 
blood. Kinetics experiments with this chloride concentration were considered initially, 
however, kinetics traces containing 0.1 and 1.0 M NaCl were indistinguishable. 
Therefore, chloride concentrations greater than 0.5 M were used. This is particularly 
advantageous for ensured stability of NAMI-A, since inhibition of chloride and DMSO 
hydrolysis of NAMI-A at high chloride concentrations have been reported.160 
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CHAPTER THREE 
3.0 Kinetics and Mechanism of Interaction of NAMI-A with Cysteamine 
3.1 Introduction 
One of the most devastating facts about cancer treatment is lack of specificity 
for cancerous cells such that an effective drug candidate has equal potential of harming 
(normal) healthy cells. According to the National Cancer Institute, cancer treatment 
options include surgery, chemotherapy, radiation therapy, biological and targeted 
therapies, all with an endless list of side effects that are sometimes lethal.182 Up to 30% 
of patients undergoing radiation-therapy for lung cancer, breast cancer, lymphoma, or 
thymoma present radiation-related symptoms.183;184 Incidences of acute adverse effects 
of chemotherapy such as bone marrow suppression, renal failure, cardiotoxicity, 
mutagenicity and emesis are well documented.185-188  
 Cancer treatment options attempt to strike a balance between beneficial and 
adverse effects, necessitating the use of agents that protect healthy cells from toxic 
effects of these treatment types.189-191 Aminothiols have been successful as chemo and 
radio protectants.192;193 Prevention of immediate and delayed effects of therapy is 
expected of an ideal protectant. A Phase III clinical trials report has proven Amifostine, 
an FDA approved aminothiol, as the only effective cytoprotectant against cisplatin-
induced cumulative renal toxicity.194;195 Amifostine was originally selected as a 
radioprotective agent by the Antiradiation Drug Development Program of the U.S. 
Army Medical Research and Development Command after synthesis and testing of 
4,400 compounds.196 The range of applications of Amifostine is on the increase (see 
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Table 3.1). Studies have demonstrated selective chemo and radio protection of normal 
cells by Amifostine.197 
 
Agent Adverse Effect 
Cisplatin Nephrotoxicity 
Neurotoxicity 
Renal toxicity 
Peripheral nerve damage 
Cyclophosphamide Pulmonary toxicity 
Fotemustine Mutagenicity 
Doxorubicin Cardiotoxicity 
Mitomycin C Hematological toxicity 
Radiation therapy Hematological toxicity 
Mutagenicity 
Carcinogenicity 
Mucosa, skin and salivary gland 
damage 
 
Table 3.1: Summary of selected anticancer agents and corresponding effects against 
which Amifostine offers protection.195;198-201 
 
In vivo, Aminofostine is dephosphorylated by alkaline phosphatase enzyme to 
the free thiol, WR-1065, which is the active metabolite (see Scheme 3-1). Alkaline 
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phosphatase is expressed more in normal cells compared to cancerous cells leading to 
higher contents of WR-1065 in normal cells.202-204 WR-1065 is structurally related to 
cysteamine, a cellular thiol (Figure 3-1). 
 
 
Scheme 3-1: Hydrolysis of amifostine to form its active metabolite, WR-1065 
 
 
Figure 3-1: 2-aminoethanethiol also called cysteamine. Structurally related to the 
active metabolite of amifostine, WR-1065. 
 
Cysteamine modulates cellular levels of glutathione205 and is an important intermediate 
in the alternative pathway of taurine biosynthesis (i.e coenzyme A degradation).206 The 
discovery of cysteamine dioxygenase emphasizes biological importance of this simple 
thiol. Cysteamine dioxygenase adds two atoms of oxygen to free cysteamine to form 
hypotaurine which is further oxidized to taurine.207-209 Cysteamine has been approved 
by the FDA for treating nephropathic cystinosis, a rare lysosomal storage disease that 
might result in kidney failure or death if unattended.210-212 Applications of cysteamine 
are on the increase with recent studies demonstrating its specific activity against 
 
35 
 
Plasmodium malaria parasite213 and potentiation of antimalaria activity of 
artemisinin.214;215  
Reports on effectiveness of cysteamine in radioprotection and chemoprotection 
are extensive.216-220 Documented effectiveness of cysteamine in cystinosis treatment, 
radio and chemo protection and its structural similarity to amifostine makes its 
interaction with NAMI-A a possibility in a combination-regimen involving NAMI-A 
and any cancer treatment against which protection is necessary. In this chapter, results 
are presented for such an interaction.  
 
 
3.2 Results  
3.2.1 Stoichiometry and Product Identification: Stoichiometric determinations 
employing measurement of residual absorbance at 390 nm of solutions containing 
varying ratios of NAMI-A and cysteamine are shown in Figure 3-2. Absorbances were 
recorded within 2 minutes of solution preparation. 
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Figure 3-2: Plot of Residual absorbance of NAMI-A against [NAMI-A]/[cysteamine] 
ratio revealing stoichiometric ratio beyond which residual absorbance persists. [NAMI-
A]/[cysteine] = 0.25, 0.33, 0.5, 1.0, 2.0, 3.0 and 4.0. 
 
A full ESI-MS spectrum of equimolar concentrations of NAMI-A and cysteamine was 
taken within the first minute of the reaction in order to identify molecular species and 
possible intermediates involved in the reaction progress (see Figure 3-3). An ESI-MS 
peak corresponding to NAMI-A was observed at 389 m/z. The small relative abundance 
of this peak is expected since the reaction occurs in the order of ~ 4 s as recorded on the 
stopped-flow. The reaction is essentially complete on comparing the time scale of the 
reaction with that of ESI-MS experiment, although the sample was run with as short a 
time-lapse as possible from mixing time. Other peaks observed in the negative mode 
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spectrum demonstrate hydrolysis of NAMI-A involving two of the axial chloride 
ligands, 352 m/z, and loss of one or both of the apical ligands 274 and 209 m/z 
respectively. The peak at 180 m/z cannot be identified at this time, although its profile 
may suggest a non ruthenium-containing species. 
 
 
Figure 3-3: Full ESI-MS (negative mode) spectrum of 1:1 ratio of NAMI-A to 
cysteamine taken within the first minute of the reaction in 50% methanol. 
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Spectrum of the same reaction in the positive mode (Figure 3-4) features 
cystamine, disulfide of cysteamine at 153 m/z. This conforms to the expected result of a 
one-electron oxidation of cysteamine which should result in cystamine. 
 
   
Figure 3-4: Full ESI-MS (positive mode) spectrum of equimolar concentrations of 
NAMI-A and cysteamine taken within the first minute of the reaction in 50 % methanol. 
Spectrum shows cystamine as the product. 
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3.2.2 Kinetics 
3.2.2.1 NAMI-A dependence: Effect of varying initial concentrations of NAMI-A on 
the reaction in 0.05 M phosphate buffer at pH 7.4 was examined, (see Figure 3-5a). The 
rate of consumption of NAMI-A increased with increasing initial NAMI-A 
concentrations.  Rate measurements were confined to the initial 2% of the reaction 
where determination of contributing species is fairly accurate before contributions from 
intermediates.   
 
Figure 3-5a: Kinetic traces of reaction in 0.05M phosphate buffer (pH 7.4) showing 
dependence on [NAMI-A] at its λmax. [Cysteamine]o = 1.0 x 10-2M; [NAMI-A]o = (a) 5.0 
x 10-5 M (b) 6.0 x 10-5 M (c) 7.0 x 10-5 M (d) 6.0 x 10-5 M  (e) 9.0 x 10-5 M (f) 1.0 x 10-4 M  
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Plots of initial rates against initial NAMI-A concentrations gave straight lines, 
indicating a linear dependence on NAMI-A (Figure 3-5b). Since [cysteamine]o is much 
greater than [NAMI-A]
 o, cysteamine concentration effectively remained unchanged 
during the reaction. The observed pseudo rate constant was then determined to be 6.85 x 
10-1 + 0.03 s-1. 
 
Figure 3-5b: Initial rate plot derived from Figure 3-5a, showing linear dependence on 
NAMI-A. [Cys]o = 1.0 x 10-3M; [NAMI-A]o = 5.0 x 10-5 M to 1.0 x 10-4 M 
 
3.2.2.2 Cysteamine dependence: Dependence of the reaction on initial concentrations 
of cysteamine (all other reaction conditions fixed) was monitored at 390 nm.  Reaction 
rate increased with increasing concentrations of cysteamine (Figure 3-6a). The 
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sigmoidal-type traces, more pronounced at low cysteamine concentrations and later also 
observed at high temperatures, might suggest autocatalysis. Initial rate plots deduced 
from this plot are nonlinear (see Figure 3-6b) which might suggest adduct formation. 
Similar effects were observed at various temperatures vis-à-vis: 15, 20, 30 and 37 oC 
(Figure 3-6c) and are summarized in Figure 3-6d. 
 
 
Figure 3-6a: Effect of cysteamine variation on the consumption of NAMI-A at 390 nm. 
[NAMI-A]o = 1.0 x 10-4 M; [cysteamine]o = (a) 2.0 x 10-3 M (b) 3.0 x 10-3 M (c) 4.0 x 
10-3 M (d) 6.0 x 10-3 M (e) 8.0 x 10-3 M (f) 1.0 x 10-2 M.  Reaction rate increased with 
cysteamine concentration.  
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Figure 3-6b: Initial rate plot derived from data shown in Figure 4a, showing nonlinear 
dependence on NAMI-A concentrations. [NAMI-A]o = 1.0 x 10-4 M; [cysteamine]o = 2.0 
x 10-3 M  to 1.0 x 10-2 M. 
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a  b  
c  d  
Figure 3-6c: Effect of cysteamine variation at temperatures 15, 20, 30 and 37 oC from a 
through d respectively. 
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Figure 3-6d: Summary of rate dependence on cysteamine at various temperatures. 
[ΝΑΜΙ-Α]ο = 1.0 χ 10-4 Μ;΄[cysteamine]ο = 2.0 χ 10-3 Μ  το 1.0 χ 10-2 Μ. 
 
3.2.2.3 Effect of ionic strength: The response of this reaction to changes in 
concentration of an inert salt (NaClO4), at constant temperature and reactants 
concentrations, was monitored at pH 7.4 without a buffering environment. Increasing 
ionic strength slowed down the reaction rate in both cases as shown in the 
representative plot, Figure 3-7 (no buffer). This suggests that the rate determining 
step(s) involve species of different charges. Although, from pKa of cysteamine, 
appreciable amount of zwitterionic cysteamine exists in solution, the net positively 
charged species should be predominant in the rate determining step.  
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Figure 3-7: Ionic strength dependence of cysteamine-NAMI-A reaction. [Cysteamine]o 
= 1.0 x 10-2 M; [NAMI-A]o =  1.0 x 10-4 M; [I]NaClO4 = (a) 1.00 x 10-4 M (b) 0.15 M (c) 
0.30 M (d) 0.45 M (e) 0.90 M 
  
3.2.2.4 Effect of chloride ion: The dependence of this reaction to changes in chloride 
ion concentrations at constant temperature and other reaction conditions (pH, reactants 
concentrations and ionic strength) was examined. Chosen chloride concentrations were 
corresponded to concentrations in the cytoplasmic matrix (~2 mM), blood/extracellular 
fluids (up to 100 mM) and in some experiments higher concentrations were used. The 
presence of small amounts of chloride ions retarded the reaction as seen in Figure 3-8, 
but increasing chloride ion concentrationsfurther, however, did not significantly affect 
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the overall rate of reaction. No observable difference was observed in the kinetics traces 
of solutions containing chloride concentrations of 0.02, 0.1, 1.0 M and higher.  
 
 
Figure 3-8: Effect of varying initial chloride concentration.[cysteamine]o = 1.0 x 10-2 
M; [NAMI-A]o =  1.0 x 10-4 M; [µ]NaClO4 = 1.0 M; [Cl-] =  0.00  M to 0.10 M  
 
3.2.2.5 Thermodynamics and activation parameters: At fixed concentrations of 
substrate, oxidant and ionic strength, the effect of temperature on the reaction was 
evaluated. Reaction rate increased proportionally with increasing temperatures as 
expected (see Figure 3-9a). The data obtained were used to construct an Arrhenius plot 
(see Figure 3-9b).  
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Figure 3-9a: Temperature dependence of cysteamine-NAMI-A reaction. [NAMI-A]o = 
1.0 x 10-4M; [cysteamine]o = 1.0 x 10-2 M , Temperature = (a) 15 oC (b) 20 oC (c) 25 oC 
(d) 30 oC (e) 37 oC, pH 7.4; Ionic strength maintained at 1.0 M using NaCl 
 
The Arrhenius plot afforded these activation parameters: entropy of activation, 
∆S≠
 
= -117 J K-1 mol-1, enthalpy of activation, ∆H≠ = 41.5 kJ mol-1 and free energy of 
activation as ∆G≠ = 76 kJ mol-1 (at 25 oC). Low positive enthalpy and distinctly 
negative entropy of activation suggests some degree of molecular ordering in the rate 
determining step. These parameters are indicative of an associative mechanism. 
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Figure 3-9b: Temperature dependence of cysteamine-NAMI-A reaction. [NAMI-A]o = 
1.0 x 10-4M; [cysteamine]o = 1.0 x 10-2 M. 
 
3.3 Μechanism 
3.3.1 Electron Transfer: Reactions were carried out at pH 7.4. At this pH, the amine 
functional group of cysteamine should be predominantly protonated since the thiol and 
amine pKa’s
 
 are 8.27 and 10.53 respectively.221  
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Although cysteamine exists predominantly in the protonated form under these reaction 
conditions, appreciable amounts of zwitter-ionic form (see R2) are also present at 13 % 
of total cysteamine after using the Henderson-Hasselbach equation.  
 
HNCHCHSH      º   HNCHCHS  	    H                                        K           R2 
  
These species react with anionic NAMI-A to form an activated complex derived from 
reactions R3 and R4. The activated complex, sitting at the maximum energy point along 
the reaction coordinate, may, however, rearrange to form products or fall back to 
reactants. Activation parameters obtained are suggestive of an associative mechanism in 
which the activated complex is more ordered in comparison to the reactants.  
 
HNCHCHSH 	 ImRuClDMSO  
   HNCHCHSH … ImRuClDMSO                      k               R3 
 
HNCHCHS 	 ImRuClDMSO  
   HNCHCHS … ImRuClDMSO                      k               R4 
 
R3 and R4 estimate the nature of the activated complex in terms of composition only, 
specific molecular arrangement of the species cannot be determined at this time. R5 and 
R6 demonstrate formation of products: the reduced NAMI-A and cystamine from the 
activated complex.  
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2HNCHCHSH … ImRuClDMSO     HNCHCHSSCHCHNH      
	   2ImRuClDMSO       	      4H                                 k                  R5 
 
2HNCHCHS … ImRuClDMSO     HNCHCHSSCHCHNH      
	   2ImRuClDMSO       	      2H                                  k                 R6 
 
Redox interactions between reduced NAMI-A and cystamine were anticipated. 
The labile nature of the reduced complex however, with a half life of ~14 s82 implies 
that reaction is effectively irreversible. This short half life taken together with reaction 
duration of ~4 s for electron transfer (measured by disappearance of charge transfer 
band of NAMI-A at 390 nm) might explain obvious absence of reduced NAMI-A from 
ESI-MS spectrum.  
 
3.3.2 Ligand Exchange: Following electron transfer process, is a series of ligand 
exchange processes involving two chloride ligands and the apical ligands, imidazole 
and dimethyl sulfoxide as described by R7- R13.  
 
ImRuClDMSO  	    HO    ImRuCl$HO% DMSO   	   Cl                        R7 
ImRuCl$HO% DMSO  	   HO    ImRuCl$HO%DMSO   	   Cl                R8 
ImRuCl$HO%DMSO           ImRuCl$HO%$OH%  	  H   	   DMSO           R9 
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ImRuCl$HO%DMSO           ImRuCl$OH%DMSO   	     H                         R10 
ImRuCl$HO%DMSO   	   HO          ImRuCl$HO%    	    DMSO              R11 
 
ImRuCl$HO%       	   HNCHCHS     
   ImRuCl$HO%    SCHCHNH   	   HO                                R12 
 
ImRuCl$HO%         RuCl$HO%   	   HO  	    Im                                        R13 
 
Results of influence of chloride ions on the reaction as seen in Figure 3.8 suggest that 
the chloride exchange reactions, R7 and R8) could be reversible. These interactions 
have been summarized graphically into Scheme 3-2.  Structures labeled F and G were 
not observed on the ESI-MS spectra (refer to Figure 3.3), however, the presence of K 
and the 352 m/z with such high relative abundance strongly suggests formation of these 
species. The 352 m/z might be due to either J or L. Formation of J will require loss of 
acidic protons from coordinated water. Availability of protons (refer to R5 and R6) in 
the reaction mixture however, might make formation of J less viable. More so, the 
nonlinear dependence of reaction on cysteamine concentration might affirm adduct 
formation as was the case with respect to L. 
Reaction scheme 3-2 exemplifies labilization and subsequent ligand exchange 
reactions that have been observed for metal-based anticancer prodrugs vis-à-vis; IndICR 
and platinum (IV) complexes33;180 Consequently, reduction of NAMI-A by cysteamine 
should enhance reactivity of NAMI-A with biomolecules, this is in agreement with 
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reports of increased antimetastactic activity of NAMI-A and adduct formation with 
transferrin, human serum and albumin in the presence of cysteine and GSH.222  
 
 
Scheme 3-2: Proposed mechanism for the reduction of NAMI-A by cysteamine and 
subsequent ligand exchange process. 
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CHAPTER FOUR 
4.0 Kinetics and Mechanistic Investigation into the Possible Activation of 
NAMI-A by 2-Mercaptoethane sulfonate 
4.1 Introduction 
Cancer still poses a significant health threat mostly due to the inability of 
individual drugs to cure cancer at clinically tolerable doses.223-225 The two exceptions to 
these are choriocarcinoma and Burtitt’s lymphoma.226 These factors have necessitated 
combination chemotherapy. 
Imidazolium trans-[tetrachloro (dimethyl sulfoxide)(imidazole)ruthenate(III)], 
NAMI-A, is an experimental prodrug that shows low host toxicity and selectively 
targets metastatic cells.74;177;181;227 NAMI-A, while being very active against metastases 
has relatively limited activity towards primary tumor.228;229 This suggests that 
administration of NAMI-A in combination with drug(s) active against primary tumor 
might present more desirable chemotherapy outcome. Likely options for this purpose 
are widely used anticancer drugs shown in Table 1. These drugs form an integral part of 
chemotherapy regimens used in cancer treatment, for instance, cisplatin is used in 50-
70% of all cancer patients most often in combination with other drug(s).230  A notable 
disadvantage with these and other drugs is their induction of nephrotoxicity.186;188;226 
Most anticancer drugs and their metabolites are eliminated through the kidneys, thus, 
making the kidneys susceptible to injury.185 
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Alkylating Agents Antimetabolites Miscellaneous 
Cisplatin Azacitidine Diaziquone 
Carboplatin Methotrexate Clofarabine 
Carmustine 6-Thioguanine Mitomycin 
Streptozocin Pentostatin Temsirolimus 
Ifosfamise   
Cyclophosphamide   
Chloroethylnitrosoureas   
 
Table 4- 1: Widely used chemotherapy drugs with inherent nephrotoxicity.185;186;188;226  
Antimetabolite: drug that interferes with normal metabolic processes within cells231  
Alkylating agent: drug that causes DNA damage by addition of alkyl groups to specific 
bases.232 
 
A combination, therefore, of NAMI-A and any of the above mentioned drugs will 
require a concurrent use of a chemoprotectant to prevent nephrotoxicity. 
Chemoprotection aims at prevention, mitigation or delay of toxicity, thereby increasing 
therapeutic index of chemotherapy without interfering with efficacy of applied drug.233 
These are all expected to improve patients’ quality of life. Failure to provide adequate 
chemoprotection during therapy may mandate withdrawal or postponement of treatment 
and consequently lowers the probability of treatment success. Sodium-2-
mercaptoethanesulfonate, MESNA, is a low molecular weight thiol in clinical use as a 
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chemoprotectant which inhibits the hemorrhagic cystitis and prevents bladder and 
kidney toxicities induced by cisplatin, ifosfamide and cyclophosphamide.234-237 
Chemoprotection by simultaneous administration of 100 mg/kg MESNA did not affect 
survival times observed with vincristine, 5-fluorouracil, doxorubicin, methotrexate, 
cisplatin, or cyclophosphamide.237;238 This current clinical utility of MESNA suggests 
that an encounter with NAMI-A should be inevitable should NAMI-A be used as part of 
a combination regimen involving any nephrotoxic cancer drug. Interestingly, the 
disulfide of MENSA, BNP7787, is currently undergoing Phase III clinical trials for 
chemoprotection. Reports have revealed the involvement of MESNA in the mechanism 
of protection of cisplatin-induced nephrotoxicity as illustrated in Figure 4-1.239-241 This 
further emphasizes the potential for interaction of MESNA with NAMI-A when 
administered in combination with cisplatin.  
 
 
Figure 4-1: Nephroprotection by BNP7787 showing involvement of MESNA.239 
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A recent study reports cure of cancer in about 60% of the animals treated for 
lung metastasis using a combination of cisplatin and NAMI-A in mouse models.242 This 
represents the most successful treatment reported for metastasis.230 Presented here is a 
first report on kinetics and mechanism of interaction of NAMI-A with MESNA under 
physiologically-relevant conditions. An understanding of this interaction is important 
for optimizing clinical use of NAMI-A with high-dose nephrotoxic agents.  
 
4.2 Results 
4.2.1 Stoichiometry and Product Identification: Stoichiometry of reaction was 
found to be 1:1 with NAMI-A reacting with MESNA to give dimeric form of MESNA 
and reduced NAMI-A as represented in S1 
 
2HSCHCHSO  	  2ImRuClDMSO     
   OS  CHCHSSCHCHSO 	 2ImRuClDMSO 	   2H     S1 
 
Figure 4-1 shows the spectral changes observed from a solution of MESNA and 
NAMI-A scanned at 30 second intervals. The charge transfer band of NAMI-A at 390 
nm decreased as the reaction progressed showing one electron reduction of NAMI-A. 
The shoulder at 345 nm initially increased and then decreased towards the end of 
reaction. Absence of an isosbestic point indicates involvement of other absorbing 
species.  
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Figure 4-1: Rapid spectral scan of aqueous solution of MESNA and NAMI-A taken at 
30 s interval. [MESNA]o = 1.5 x 10-4 M; [NAMI-A]o = 5.0 x 10-5 M. 
 
Reduced form of NAMI-A, [ImRuCl4dmso]2-, has been reported to have a half 
life of approximately 14 s.82  Upon formation, it is expected that this labile species will 
be rapidly hydrolyzed in these aqueous reaction conditions. A full electrospray 
ionization mass spectrum of the stoichiometric solution was taken in the negative mode 
within the first minute of reaction (Figure 4-2a). The spectrum features NAMI-A at m/z 
= 389 and MESNA at m/z = 140 being the most abundant. A small peak at m/z = 
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139.96 represents the already formed disulfide of MESNA. No peak was observed for 
the reduced NAMI-A at m/z = 194 since it is extremely labile.  
 
 
Figure 4-2a: Negative ESI-MS spectrum of a stoichiometric solution of MESNA and 
NAMI-A within the first minute of start of reaction. 
 
 Other crucial features of this spectrum are the group of peaks at m/z ~ 208, 243 
and 321. The 208 m/z peaks might seem insignificant (5 % relative abundance) but 
evidence from other studies in this dissertation (Chapters 3 and 6) suggest these are ions 
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formed from reduced NAMI-A with a basic structure, [RuCl2(H2O) 2]. Figure 4-2a 
displays [RuCl2(H2O) 2+H] and [RuCl2(H2O) 2-H] with the same relative abundance. 
243 and 321 m/z are due to ionization since NAMI-A without reductant shows these 
peaks.82 Spectrum in Figure 4-2b, taken five minutes after Figure 4-2a shows decrease 
in both NAMI-A and MESNA peaks with simultaneous growth of the disulfide of 
MESNA.  
 
Figure 4-2b: Negative ESI-MS spectrum of the same solution in Figure 4-2a taken five 
minutes later showing the depletion of both NAMI-A peak at 389.8300 m/z and MESNA 
peak at 140.9684 m/z with simultaneous growth of disulfide of MESNA at 139.9612 m/z 
and decay of MESNA.  
T: FTMS - p ESI Full ms [100.00-401.51]
120 140 160 180 200 220 240 260 280 300 320 340 360 380 400
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
139.9612
140.9684
241.7798
240.7809
171.9331 245.7784142.9643 389.8300239.7804 321.7923247.7757208.8092 391.8293386.8327138.9535 237.7814 323.7930317.7946273.8418 384.8343189.2303 225.8118 351.8556249.7727
173.9288
121.0297 157.1235 327.7872282.9250
60 
 
Figure 4-2c, taken at 5 minutes shows the disulfide as most abundant, demonstrating 
progress of the reaction towards completion, according to stoichiometric reaction S1. 
 
 
Figure 4-2c: Negative ESI-MS spectrum of solution in Figure 3-2a taken ten minutes 
later showing disulfide of MESNA as the major peak. 
 
Of note is the nature of the product, dimeric form of MESNA (referred to as 
BNP7787),239 and its relevance to cancer chemotherapy. BNP7787 has demonstrated 
chemoprotection that surpasses that of MESNA and may protect against cisplatin-
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induced nephrotoxicity without interfering with efficacy, thus suggesting a more 
improved quality of life for patients.241;243;244 
 
4.3 Kinetics 
4.3.1 NAMI-A Dependence 
Effect of varying initial concentrations of NAMI-A on the reaction in 0.1 M 
phosphate buffer at pH 7.4 was examined (see Figure 4-3a). The rate of consumption of 
NAMI-A increased with increasing initial NAMI-A concentrations.  Absorbance traces 
at 390 nm in Figure 4-3a (and all other subsequent traces which monitor consumption of 
NAMI-A) show what might appear, erroneously, as mild autocatalysis.  This peak at 
390 nm is not entirely isolated and is influenced by contribution from a peak at 345 nm, 
which appears as a shoulder to the 390 nm peak.  Since the peak at 345 nm initially 
increases, one expects a positive contribution, measured at 390 nm from this peak.  As 
the reaction proceeds, however, the peak at 345 nm starts to fall, with a concomitant 
decrease in its contribution at 390 nm.  Thus the observed rate of decrease of the peak at 
390 nm will be enhanced, without necessarily an increased decrease in rate of loss of 
NAMI-A. There is no stoichiometric link between NAMI-A and the intermediate that 
absorbs at 345 nm, thus initial rates for all our kinetics determinations were confined to 
a very short initial part of the reaction before establishment of intermediates.   
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Figure 4-3a: Kinetic traces of reaction in 0.1M phosphate buffer (pH7.4) showing 
dependence on [NAMI-A] at its λmax. [MESNA]o = 5.0 x 10-2M; [NAMI-A]o = (a) 5.0 x 
10-5 M (b) 6.0 x 10-5 M (c) 7.0 x 10-5 M (d) 6.0 x 10-5 M  (e) 9.0 x 10-5 M (f) 1.0 x 10-4 M 
 
Plot of initial rates against initial NAMI-A concentrations gives a straight line, with an 
intercept kinetically indistinguishable from zero, suggesting a linear dependence on 
NAMI-A (Figure 4-3b). A bimolecular rate constant of 7.07 x 10-1 + 0.06 M-1s-1 was 
deduced from the data shown in Figures 4-3a and b.  
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Figure 4-3b: Initial rate plot derived from Figure 4-3a, showing linear dependence on 
NAMI-A. [MESNA]o = 2.0 x 10-3M; [NAMI-A]o = 5.0 x 10-5 M to  9.0 x 10-5 M 
 
4.3.2 MESNA Dependence. 
Effect of variation of initial concentrations of MESNA was also monitored at 
390 nm.  The reaction rate monotonically increased with increasing concentrations of 
MESNA with no apparent saturation but with an apparent slight increase in rate at high 
MESNA concentrations (Figure 4-4a). Initial rate plots deduced from this plot, Figure 
4-4b, again show a linear dependence on MESNA concentrations. Increase in rate 
observed at the tail end of the traces is due to the aforementioned absorbance 
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contribution at 345 nm which magnifies rate of decrease in observed absorbance at 390 
nm.  Sigmoidal-type traces are much more pronounced at higher MESNA 
concentrations, and hence the expected deviations at high MESNA concentrations. 
 
 
Figure 4-4a: Effect of MESNA variation on the consumption of NAMI-A at 390 nm. 
[NAMI-A]o = 1.0 x 10-4 M; [MESNA]o = (a) 1.0 x 10-2 M (b) 2.0 x 10-2 M (c) 3.0 x 10-2 
M (d) 4.0 x 10-2 M (e) 5.0 x 10-2 M (f) 6.0 x 10-2 M (g) 7.0 x 10-2 M.  
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Figure 4-4b: Initial rate plot derived from Figure 4-4a, showing linear dependence on 
[MESNA]o 
 
4.3.3 Buffer and pH Effects. 
In the absence of buffer ions, varying initial concentration of MESNA 
influenced the reaction in similar manner as were obtained when reaction was carried 
out at pH 7.4, compare Figures 4-4a and c. The slower rate in the absence of buffer 
might be due to reported stability of NAMI-A at lower pHs.245 At much lower pH 
values of 5 through 3, lower rates were observed and sigmoidal characteristics on the 
traces became more pronounced as pH decreased, see Figure 4-4d.  
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Figure 4-4c: Effect of MESNA variation on the consumption of NAMI-A at 390 nm. 
Reaction not buffered. [NAMI-A]o = 1.0 x 10-4 M; [MESNA]o = (a) 1.0 x 10-2 M (b) 2.0 
x 10-2 M (c) 3.0 x 10-2 M (d) 4.0 x 10-2 M (e) 5.0 x 10-2 M (f) 6.0 x 10-2 M (g) 7.0 x 10-2 
M. Reaction is slower than observed at pH 7.4, compare Figure 4-4a. 
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Figure 4-4d: Influence pH on reaction rate. Reaction in 0.1 M phosphate buffered at 
pH 3.0 proceeded slowly compared to pH 4.0 and 5.0. [NAMI-A]o = 1.0 x 10-4M; 
[MESNA]o = 5.0 x 10-2 M 
 
4.3.4 Temperature dependence.  
At constant ionic strength, concentrations of NAMI-A and MESNA, the effect 
of temperature on the reaction was evaluated. Reaction rate increased proportionally 
with increasing temperatures as would be expected from standard Arrhenius kinetics 
(see Figure 4-5a), suggesting the existence of a single dominant rate-determining step. 
The data obtained were used to construct an Arrhenius plot (see Figure 4-5b). 
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Activation parameters deduced using information obtained from the Arrhenius plots are: 
entropy of activation, ∆S≠
 
= -178.12 + 0.28 J K-1mol-1, enthalpy of activation, ∆H≠ = 
20.64 + 0.082 kJ mol-1 and free energy of activation as ∆G≠ = 75.89 + 1.76 kJ mol-1 at 
37 + 0.1 oC and pH 7.4. The distinctly negative entropy of activation suggests some 
degree of molecular ordering in the rate determining step. These parameters are 
indicative of an associative mechanism. 
 
 
Figure 4-5a: Temperature dependence of the reaction between NAMI-A and MESNA 
(0.1 M phosphate buffer, pH 7.4). Reaction rate increased with temperature increase. 
[MESNA]o = 5.0 x 10-2M; [NAMI-A]o = 1.0 x 10-4M; Temp = (a) 10o C (b) 15o C (c) 20o 
C (d) 25o C (e) 30o C (f) 37o C.  
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Figure 4-5b: Arrhenius plot extracted from study of effect of temperature variation on 
the reaction for determination of activation parameters. 
 
4.3.5 Effect of ionic strength:  
The response of the present reaction to changes in concentration of an inert salt, 
at constant temperature and reactants concentrations, was examined (Figure 4-6). 
Increasing ionic strength increased the rate of reaction. This might suggest that the rate 
determining step(s) contain species of similar charges. 
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Figure 4-6: Influence of ionic strength on reaction rate. Ionic strength increase from 
(a) to (e) increased the reaction rate as shown. [NAMI-A]o = 1.0 x 10-4M; [MESNA]o = 
5.0 x 10-2 M; [I] NaClO4 = (a) 0.05 M (b) 0.10 M (c) 0.20 M (d) 0.30 M (e) 0.40M. 
 
4.4 Mechanism 
Ionization of MESNA in aqueous solution is represented in R1. Under reaction 
conditions of pH 7.4, predominant species is the monoanionic as seen in this reaction. 
Dianionic form (see R2) is expected to be present in quantifiable amounts based on the 
Henderson-Hasselbach equation. 
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HSCHCHSONa       º       HSCHCHSO        	        Na                                      R1 
HSCHCHSO             º      S  CHCHSO         	        H                          K          R2 
 
These species react with anionic NAMI-A to form associative complexes (see R3; R4) 
as indicated by deduced activation parameters. The activated complexes then proceed to 
form BNP7787 and reduced NAMI-A as products as shown in R5 and R6.  
 
HSCHCHSO   	  ImRuClDMSO  
   HSCHCHSO   … ImRuClDMSO                      k                  R3 
 
S  CHCHSO   	   ImRuClDMSO  
    S  CHCHSO   … ImRuClDMSO                      k                  R4 
 
2HSCHCHSO   … ImRuClDMSO   
  OS  CHCHSSCHCHSO    	  2ImRuClDMSO   2H         R5 
 
2 S  CHCHSO   … ImRuClDMSO     
      OS  CHCHSSCHCHSO     	    2ImRuClDMSO             R6 
 
Results of the ESI-MS experiments (Figure 4-2a-c) suggests a clean conversion 
of NAMI-A to the reduced dianion form. The absence of an isosbestic point on the 
multiple UV/Vis spectra suggests involvement of multiple absorbing species. Redox 
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interaction between the products was anticipated, however, the nature of these species 
in terms of charge strongly indicate prevention of such interactions due to electrostatic 
repulsions.  
 Reaction rate measured as the rate of disappearance of [ImRuCl4DMSO]-, 
NAMI-A is defined as: 
 
Rate -  kRSHImRuClDMSO  	   kRSImRuClDMSO                              E1    
 
where RSH and RS- represent protonated and deprotonated MESNA respectively as 
shown in R1 and R2. Results obtained from ionic strength effects demonstrate that the 
reaction of RS- is rate limiting thus indicating that k1 >> k2 and E1 reduces to  
 
                           Rate     -       kRSImRuClDMSO                                                 E2 
 
E2 can be expressed in terms of initial MESNA concentration which is distributed 
between RSH and RS-. From mass balance, 
 
                             RSH/     -        RSH   	      RS                                                        E3  
 
Combining E3 with Henderson-Hasselbach equation, a ratio of [RS-] to [RSH] can be 
derived. Substitution for [RSH] using R2 results in the rate law;   
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       Rate     -      012RSH/ImRuClDMSO

H$1 	 1034356%                                                           E4 
 
which in conditions of overwhelming excess of MESNA can be written as  
 
                             Rate     -       27ImRuClDMSO                                                        E5 
where  
                              27        -      012RSH/H$1 	 1034356%                                                        E6 
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CHAPTER FIVE 
5.0 Kinetics and Mechanism of interaction of NAMI-A with Glutathione 
5.1 Introduction 
Intracellular thiols are essential for maintenance of cellular redox homeostasis in 
living systems.246 Glutathione (GSH) is the most abundant and most important cellular 
antioxidant in animal cells with concentrations up to 10 mM in the cytoplasm and 2 – 
20 µM in extracellular fluids.247;248 It performs cytoprotectivity against reactive oxygen 
and nitrogen species vis: hydrogen peroxide, peroxynitrite, lipid peroxyl, hydroxyl, 
nitric oxide and superoxide radicals.249 These reactive species have been implicated in 
the pathogenesis of various disease states including atherosclerosis, hypertension, 
ischemia/reperfusion injury, cardiovascular disease, diabetes mellitus, 
neurodegenerative diseases (Alzheimer’s and Parkinson’s diseases), rheumatoid 
arthritis, cancer and ageing 246;250;251 Participation of GSH in various metabolism and 
regulatory processes such as synthesis of prostaglandins, cell proliferation and apoptosis 
is well documented.248;252-254 Its direct and indirect involvement in various important 
biochemical processes is further illustrated in Figure 5-1,255 where it is shown to act as a 
center wheel influencing all featured processes. 
Interactions of a drug with biomolecules and other xenobiotics influence its 
absorption, distribution, metabolism, excretion and toxicity (ADMET) properties and 
ultimately its activity. These properties are determinants of a drug’s clinical relevance. 
Drugs are metabolised either to active or inactive metabolites by interaction with 
proteins and non-protein biomolecules. Such interactions impact drug efficacy 
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positively or otherwise. Interaction of any xenobiotic with GSH invariably translates to 
potential for modulation of processes involving GSH.256  
 
 
Figure 5-1: A representation of the GSH involvement in important cellular processes. 
(Modified figure adapted from Mitchell, J.B. & Russo, A. 1987 Br. J. Cancer Suppl. 
8:96-104)255  
 
Decrease in GSH levels impairs a cell’s ability to protect itself thereby 
increasing sensitivity to effects of toxic substances. It is then not surprising that higher 
levels of GSH in cancer cells are associated with observed resistance to 
chemotherapeutic agents.257-259 This is in agreement with mounting evidence that tumor 
cells have higher levels of GSH compared to normal healthy cells.260-262  
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There is great potential for interaction between NAMI-A and GSH considering 
the extent of GSH involvement in many processes of biological significance. In view of 
the above, this chapter reports on the investigation conducted on the reactivity of 
NAMI-A with GSH in hopes of better understanding of mechanism of action of this 
promising prodrug. 
 
5.2 Results and Discussion 
5.2.1 Stoichiometry and Product Identification: Absorbance measurement at 390 
nm of varying ratios of NAMI-A to GSH afforded determination of reaction 
stoichiometry. A 1:1 ratio represented by R1 was obtained (GSSG stands for oxidized 
glutathione). 
 
2GSH 	 2ImRuClDMSO   GSSG 	  2ImRuClDMSO 	 2H                        R1 
 
An absorption profile of a solution containing about 1:3 ratio of GSH to NAMI-A was 
recorded at 30 s intervals. Consumption of NAMI-A was observed as the reaction 
progressed as demonstrated by reduction at 390 nm (Figure 5-2a). The disappearance of 
this band occurred with concomitant formation of a new band at ~339 nm which 
progressively shifted to lower wavelength. Growth of the new peak represents 
conversion of reduced NAMI-A to a new absorbing form, supposedly through ligand 
exchange. Kinetic observation at ~339 nm could unveil some information regarding the 
species present. Several attempts to study reaction kinetics at this wavelength however, 
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demonstrated that consistent results could not be obtained under these reaction 
conditions. Contributions from multiple species might be responsible. 
 
 
Figure 5-2a: Multiple spectral scans showing absorption profile as reaction progressed 
of a GSH- NAMI-A reaction mixture. Spectral interval was 30 s. [NAMI-A]o = 1.5 x 10-4 
M; [GSH]o = 5.0 x 10-4 M. 
 
A continuous spectral scan of the same solution as shown in Figure 5-2a 
revealed a decrease in the shifting 339 nm peak followed by an increase in absorption 
over the entire visible wavelength (Figure 5-2b). Blue shift in absorbance maximum and 
absence of well-defined isosbestic points might be suggestive of progress of reaction 
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towards product formation through various intermediates. Similar observations had 
been reported for GSH oxidation by chromium acetate cluster.263 
 
 
Figure 5-2b: Multiple spectral scans of same solutions observed in Figure 5-2a. The 
new peak grew to a maximum and later decreased. Absorption over entire spectrum is 
observed with the disappearance of this peak. 
 
Identification of all observable molecular species present in a dynamic reaction 
mixture and after completion of reaction is key to establishing pathway for interaction 
of reactants to form products. A full ESI-MS spectrum of solution containing a 
stoichiometric ratio of NAMI-A and GSH was taken in the negative mode within the 
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first minute of the reaction in order to identify molecular species involved (Figure 5-3). 
Observed ions were monoanionic NAMI-A, [RuCl4DMSO]-, [GSH-H]- and RuCl4 at 
389, 321 and 243 m/z respectively. One electron oxidation of GSH should result in 
formation of dimeric GSH and dianionic NAMI-A.  
 
 
Figure 5-3: Full ESI-MS spectrum of stoichiometric solution of  NAMI-A and 
glutathione within the first minute of the reaction. (50% methanol, negative mode) 
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 An ESI-MS spectrum of the same solution taken in the negative mode a minute 
later is shown in Figure 5-4. Same peaks as the ones observed in Figure 5-3 were 
present with the appearance of a new peak at 611 m/z displaying formation of dimeric 
GSH, GSSG.  
 
 
Figure 5-4: Full ESI-MS spectrum of solution in Figure 5-1 taken a minute later. 
Formation of GSSG was observed. (50% methanol, negative mode) 
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Dianionic NAMI-A was not observed, its obvious absence could be attributed to its 
short half life. No ions indicating aquation of any of the apical or axial ligands were 
observed. In the positive mode (Figure 5-5), only ions corresponding to GSH and GSSG 
were observed in significant relative abundances. 
 
 
Figure 5-5: Full ESI-MS spectrum of equimolar concentrations of NAMI-A and 
glutathione ran in the positive mode, showing formation of product, GSSG.  (solvent-
50% methanol) 
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5.2.2 Kinetics 
5.2.2.1 NAMI-A dependence: The peak serum concentration, Cmax, of NAMI-A 
following administration of recommended safe dose of 300 mg/m2/day ranged on the 
average between 1.58 x 10-4 M and 4.00 x 10-4 M for day 1 and day 5 respectively. Sets 
of initial NAMI-A concentrations were chosen such that highest concentration used is at 
least bioavailable. Under pseudo first-order conditions of excess GSH (100 – 200 fold), 
effect of varying initial concentrations of NAMI-A on the reaction at pH 7.4 was 
examined, see Figure 5-6a.  
 
Figure 5-6a: Kinetic traces of reaction in 0.1M phosphate buffer (pH 7.4) showing 
dependence on [NAMI-A] at its λmax. [GSH]o = 1.0 x 10-2M; [NAMI-A]o = (a) 5.0 x 10-5 
M through (f) 1.0 x 10-4 M 
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The rate of consumption of NAMI-A increased with increasing initial NAMI-A 
concentrations. Initial rates deduced from these data were employed to give Figure 5-
6b, plot of initial rates against NAMI-A concentrations indicates a linear dependence on 
NAMI-A. Pseudo first-order rate constant was then deduced to be 7.42 x 10-3 + 0.0004 
s-1 
 
Figure 5-6b: Initial rate plot derived from Figure 3.5a, showing linear dependence on 
NAMI-A. [GSH]o = 1.0 x 10-3M; [NAMI-A]o = 5.0 x 10-5 M to  1.0 x 10-4 M 
 
5.2.2.2 GSH Dependence: Dependence of the reaction on initial concentrations of GSH 
(all other reaction conditions fixed) was monitored at 390 nm. Several independent runs 
of this experiment were performed to confirm the observed trend. A representative plot 
of the results, Figure 5-7, demonstrates independence of reaction rate on initial GSH 
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concentrations. The zero-order dependence of this reaction on GSH concentration thus 
renders the pseudo-first-order rate constant equivalent to overall reaction rate constant.  
 
 
Figure 5-7: Effect of increasing initial GSH concentration on the consumption of 
NAMI-A at 390 nm. [NAMI-A]o = 1.0 x 10-4M; [I] = 1.0 M, [GSH]o varies from 2.0 x 
10-3 M to 8.0 x 10-3 M   
 
This suggests that GSH is not involved in the rate-determining step and does not affect 
the transition state. This observation might be suggestive of a chelate formation process. 
GSH possesses multiple potential binding sites: carboxylic acid, amino, amide and 
sulfhydryl groups, all of which cannot be coordinated simultaneously to the ruthenium 
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center. Species demonstrating the formation of coordinated GSH were not observed on 
the ESI-MS.  
 
5.2.2.3 Effect of ionic strength: Under unbuffered conditions of constant temperature, 
oxidant and reductant concentrations, the influence of varying concentrations of an inert 
salt (NaClO4) was evaluated to establish effect of ionic strength on the reaction. 
Increasing ionic strength slowed down the reaction rate suggesting that the rate 
determining step contain species of opposite charges. 
 
5.2.2.4 Thermodynamic and activation parameters: Temperature dependence of the 
reaction was isolated with all other reaction conditions were fixed. Reaction rate 
increased proportionally with increasing temperature (see Figure 5-8a). Rate constants 
for individual temperature conditions were obtained using initial rate plots shown in 
Figure 5-8b. The derived rate constants were used to construct an Arrhenius plot, Figure 
5-8c, resulting in the following activation parameters: entropy of activation, ∆S≠
 
= -
100.6 J K-1 mol-1, enthalpy of activation, ∆H≠ = 55.1 kJ mol-1 and free energy of 
activation as ∆G≠ = 85 kJ mol-1(25 oC). The distinctly negative entropy of activation 
suggests a more ordered activated transition state compared to the reactants and is 
indicative of an associative mechanism. 
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Figure 5-8a: [NAMI-A]o = 1.0 x 10-4 M; [GSH]o = 5.0 x 10-2 M , Temperature = (a) 15 
oC (b) 20 oC  (c) 25 oC (d) 30 oC ; pH 7.4; Ionic strength maintained at 1.0 M using 
NaCl 
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Figure 5-8b: Rate plot from data shown in Figure 5-8a. All reaction conditions same as 
shown for Figure 5-8a. 
 
 
Figure 5-8c: Arrhenius plot extracted from study of effect of temperature (Figure 5-8a) 
for determination of activation parameters. 
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5.3 Μechanism 
GSH has four pKa values: 2.12, 3.59, 8.75 and 9.65 for its carboxylic, thiol and 
amine functional groups. At pH 7.4, at which reactions were performed, both carboxylic 
groups are expectedly deprotonated while thiol and amine groups are protonated.221  
These dissociations are represented by R1-R3, where HO2CCH(NH2)(SH)RCO2H 
represents GSH.  
 
HOCCH$NH%$SH%RCOH    º   O  CCH$NH%$SH%RCOH     	    H      K     R1 
O  CCH$NH%$SH%RCOH     º      O  CCH$NH%$SH%RCO     	     H      K     R2  
O  CCH$NH%$SH%RCO   	     H   º      O  CCH$NH%$SH%RCO     K     R3 
 
GSH will have a predominant net charge of -1. All of the different GSH forms will react 
with NAMI-A to form more ordered transition state, see R4 – R6. 
 
O  CCH$NH%$SH%RCOH  	   ImRuClDMSO   
              O  CCH$NH%$SH%RCOH … ImRuClDMSO                                k     R4   
  
O  CCH$NH%$SH%RCO   	   ImRuClDMSO   
                         O  CCH$NH%$SH%RCO. . . ImRuClDMSO                          k     R5  
 
O  CCH$NH%$SH%RCO   	   ImRuClDMSO   
                O  CCH$NH%$SH%RCO. . . ImRuClDMSO                           k     R6 
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Representing all associative complexes by X and all different forms of glutathione by 
GSHT, the reaction can be written as R7 
 
                       ImRuClDMSO      	    GSH:     º     X                                             K          R7  
                                                  X                  Products                                              2B          R8  
 
where products are oxidized GSSG and [ImRuCl4DMSO]2-. Rate of product formation 
can then be written as 
                                                Rate     -       2BX                                                                    E4 
From R7,   
                                                  0   -   
ImRuClDMSOGSH:
X                                      E5 
From mass balance,   
 
                 ImRuClDMSO          -       ImRuClDMSO /    C    X                            E6 
 
substituting for [ImRuCl4DMSO-] in E5 implies 
 
                           0   -   $ImRuClDMSO / 
  C X%GSH:
X                                        E7 
and  
                           X    -   ImRuClDMSO / 
 GSH:
0  	 GSH:                                                         E8 
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Substituting for [X] in the rate expression, E5, 
 
                           Rate   -   2BImRuClDMSO / 
 GSH:
0  	 GSH:                                                E9 
 
The reaction shows a complex dependence on glutathione concentration as seen in E9. 
At low [GSH], where [GSH]T << K4, the rate becomes first order in [GSH] but at high 
[GSH], when [GSH] >> K4, rate becomes zero order in [GSH]. At high [GSH] under 
which reaction was performed,  
 
                           Rate   -   2BImRuClDMSO / 

0                                                        E10 
 
which can be written as 
 
                              Rate   -   27ImRuClDMSO /                                                       E11 
 
where ko is k5/K4. This is in agreement with experimental observation as demonstrated 
by Figure 5.7. 
 
Ligand substitution reactions are expected to occur especially following formation of 
the reduced form of NAMI-A. Evidence is lacking however, on suggestion of possible 
structures.  
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 In conclusion, independence of NAMI-A reaction with GSH on initial GSH 
concentrations might suggest that administration of NAMI-A will not adversely affect 
cellular detoxification (those dependent on GSH), in agreement with its reported low 
host toxicity.162  
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CHAPTER SIX 
6.0 Kinetics and Mechanism of interaction of NAMI-A by L-Cysteine 
6.1 Introduction 
Cysteine is a non-essential amino acid that exists in various forms in vivo due to 
the different accessible oxidation states of sulfur, -2 to +6. It is the only sulfur 
contributor and the rate-limiting substrate in the biosynthesis of GSH, the most 
abundant non-protein antioxidant.264 The ability of cysteine to undergo redox cycling is 
involved in many protein functions and redox-reactions in biological systems. Cysteine 
has been reported to be one of the few biological thiols that have inhibitory effects on 
direct acting and indirect-acting mutagens.265  
Cysteine is a component responsible for many protein/enzyme structure and 
functions by modifications to the sulfhydryl functional group.266 The most abundant 
protein found in plasma is Human serum albumin (HSA) which transports blood solutes 
to target organs and maintain pH and osmotic pressure. HSA contains 35 cysteine 
residues in the form of 17 pairs of intramolecular disulfides and one free thiol, Cys-34. 
It is noteworthy that this lone free thiol in HSA accounts for almost 80 % of plasma 
thiol and most of its antioxidant capacity.267-269  
Mutation of tumor suppressor gene, p53, is a common characteristic of a wide 
variety of human cancers.270-273 This is not surprising since p53 plays significant role in 
a wide range of biochemical processes including: cell cycle regulation, DNA repair, 
programmed cell death among others.274 p53 protein contains 393 amino acids, 
modifications of cysteine residues in its central core (see Figure 6-1) critically affects its 
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functions. This is largely due to occurrence of most p53 interactions with target proteins 
in the central core.274-276 Report has also shown involvement of cysteine residues in 
suppression of transactivation  and transformation functions of p53.277  
 
 
Figure 6-1: Functional domains of p53. The DNA-binding domain contains 10 cysteine 
residues that affect its functions. (Adapted from Kim, D. et al 274) 
 
 Also of importance is the role of cysteine in the activity of macrophage 
migration inhibitory factor, MIF, a protein involved in cell-mediated immunity, 
immuno-regulation, and inflammation. It effectively modulates p53 activities. It has 
been reported that a specific cysteine residue, 81, (Cys-81) plays a critical role in MIF-
induced inhibition of p53 activity.278 
 Studying interaction of a drug candidate with cysteine can be regarded in one 
part, as investigating the reaction of the potential drug with a free amino acid and in 
another model the interaction of such drug candidate with all intracellular peptides, 
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proteins and enzymes containing cysteine residues. An investigation of the reactivity of 
NAMI-A with cysteine is therefore of high biological relevance. Results are thus 
presented in this chapter for the reactivity of NAMI-A with cysteine. 
 
6.2 Results and Discussions 
6.2.1 Stoichiometry and Product Identification: Reaction stoichiometry was 
determined using residual absorbance measurements of different ratios of NAMI-A to 
cysteine recorded within 10 minutes of solution preparation. The plot of residual 
absorbance at 390 nm against NAMI-A : cysteine ratio, Figure 6-2, clearly demonstrate 
significant residual NAMI-A in solution at ratios above the stoichiometry. Therefore, 
one mole of cysteine reacts with one mole of NAMI-A to form cystine (disulfide of 
cysteine) and reduced form of NAMI-A as shown in reaction R1. RSH, RSSR, 
[ImRuCl4DMSO]- and [ImRuCl4DMSO]2- represent cysteine, cystine, NAMI-A and 
reduced NAMI-A respectively. 
 
2RSH 	 2ImRuClDMSO   RSSR 	  2ImRuClDMSO 	 2H                         R1 
 
 Figure 6-3 shows the spectral changes observed from a solution of cysteine and 
NAMI-A scanned at 30 second intervals. The characteristic absorption of NAMI-A at 
390 nm decreased as the reaction progressed indicating conversion of [ImRuCl4DMSO]- 
to [ImRuCl4DMSO]2-.  
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Figure 6-2: Plot of Residual absorbance of NAMI-A against NAMI-A/cysteine revealing 
stoichiometric ratio beyond which residual absorbance persists. [NAMI-A]/[cysteine] = 
0.25, 0.33, 0.5, 1.0, 2.0, 3.0 and 4.0. 
 
 
Figure 6-3: Rapid spectral scan of solution of cysteine and NAMI-A taken at 5 s 
interval. [cysteine]o = 4.0 x 10-4 M; [NAMI-A]o = 1.0 x 10-4 M; no added buffer. 
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Absence of clearly defined isobestic points might suggest involvement of 
intermediates of kinetic significance during this reduction reaction. A full electrospray 
ionization mass spectrum of stoichiometric solution was taken in the negative mode 
(Figure 6-4a) within the 60 s of mixing. Ions representing [ImRuCl4DMSO]-, 
[RuCl4DMSO]-, [RuCl4]- and [Cys-H]- were observed at 390, 322, 244  and 120 m/z 
respectively. One electron oxidation of GSH should result in formation of cystine and 
dianionic NAMI-A. An ESI-MS spectrum of the same solution taken in the negative 
mode a minute later, Figure 6-4b, demonstrates cystine formation ([cystine-H] with 239 
m/z). The peak at 209 m/z was not stable; compare Figure 6-4a and b. The m/z changed 
between scans, this could mean multiple ions with about the same m/z. Ions showing 
most abundance at this m/z have a basic structure, [RuCl2(H2O) 2], switching between  
[RuCl2(H2O) 2+H] and [RuCl2(H2O) 2-H]. These could arise from: loss of both apical 
ligands from reduced NAMI-A with exchange of two of the Cl- for aquo ligands; or 
electron transfer to the Ru3+ center of 243 and 321 m/z from cysteine followed by 
appropriate ligand exchange. However, the lack of corresponding increase in relative 
abundance of the 209 peak with consumption of 243 and 321 m/z strongly support 
formation from reduced NAMI-A. In the positive mode, formation of cystine with 241 
m/z is confirmed, Figure 6-4c.  
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Figure 6-4a: Full ESI-MS (negative mode) spectrum of 1:1 ratio of NAMI-A to Cysteine 
taken within the first minute of the reaction in 50% methanol. 
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Figure 6-4b: Full ESI-MS (negative mode) spectrum of 1:1 ratio of NAMI-A to 
Cysteine taken a minute later. Showing cystine and hydrolyzed NAMI-A (Solvent is 50% 
methanol). 
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Figure 6-4c: Full ESI-MS (positive mode) spectrum of product solution of 1:1 ratio of 
NAMI-A to Cysteine showing formation of cystine (t = 3 mins).  
 
6.2.2 Kinetics 
6.2.2.1 NAMI-A Dependence: Under pseudo-first order conditions of excess cysteine, 
dependence of the present reaction on NAMI-A concentration was examined. Reaction 
rate increased with increase in initial NAMI-A concentrations as seen in Figure 6-7. 
Initial rate plot deduced from this confers a linear dependence on cysteine, see Figure 6-
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7 inset. Under these reaction conditions, cysteine concentrations effectively remained 
unchanged during the reaction leading to deduction of an observed rate constant of 9.40 
x 10-2 + 0.005 s-1. 
 
 
Figure 6-7: Kinetic traces of reaction in phosphate buffer (pH 7.4) showing 
dependence on [NAMI-A] at its λmax , 390 nm. [cysteine]o = 5.0 x 10-2M; [NAMI-A]o = 
(a) 5.0 x 10-5 M (b) 6.0 x 10-5 M (c) 7.0 x 10-5 M (d) 6.0 x 10-5 M  (e) 9.0 x 10-5 M (f) 1.0 
x 10-4 M. Inset: Initial rate plot showing linear dependence on NAMI-A. 
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6.2.2.2 Cysteine Dependence: Influence of varying initial concentration of cysteine 
was examined under pH 7.4 and in condition of no added buffer. Rate of reaction 
increased with increasing initial cysteine concentration as seen in Figures 6-8a and b. 
Reactions rates were faster at pH 7.4 than no added buffer conditions.  
  
 
Figure 6-8a: Effect of changing initial concentrations of cysteine on NAMI-A-cysteine 
reaction at pH 7.4.  [NAMI-A]o = 1.0 x 10-4 M; [Cysteine]o = (a) 4.0 x 10-3 M (b) 6.0 x 
10-3 M (c)8.0 x 10-3 M (d) 1.0 x 10-2 M (e) 1.2 x 10 -2 M. Inset: Plot of initial rate 
deduced from cysteine dependence conferring a linear dependence on cysteine.  
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Documented stability of NAMI-A at lower pH should be considered responsible for this 
observation.84;245 Difference is only expected in rates under the two conditions. 
 
 
Figure 6-8b: Effect of changing initial concentrations of cysteine on NAMI-A-cysteine 
reaction under same reaction conditions with Figure 6-8a except for the absence of 
buffer. 
 
6.2.2.3 Effect of ionic strength: Reaction rate is often affected by ions of reactants. 
This is corrected for by maintaining constant ionic strength, however, the effect of ionic 
strength can be isolated by varying amounts of an added inert salt. With reactant 
concentrations and other reaction conditions maintained constant, response of cysteine-
NAMI-A reaction was evaluated. A positive salt effect was observed, see Figure 6-9. 
This is suggestive of involvement of similarly charged ions in the rate limiting step. 
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Figure 6-9: Effect of changing ionic strength on NAMI-A-cysteine reaction.  [NAMI-A]o 
= 1.0 x 10-4 M; [Cysteine]o = 4.0 x 10-3 M; Ionic strength maintained by addition of 
NaClO4= (a) no added NaClO4 (b) 0.1 M (c) 0.2 M (d) 0.3 M (e) 0.4 M (f) 0.5 M (g) 0.6 
M (h) 0.7 M. Reaction rate increased with increasing ionic strength. 
 
6.2.2.4 Thermodynamic and activation parameters: Effect of varying temperature 
was evaluated under conditions of constant ionic strength, substrate and oxidant 
concentrations and pH of 7.4 (phosphate). Reaction rate increased with increasing 
temperatures as expected (see Figure 6-10a). The data obtained were used to construct 
an Arrhenius plot (see Figure 6-10b). Activation parameters calculated from this 
Arrhenius plot at 25 oC are: entropy of activation, ∆S≠
 
= -200.6 J K-1 mol-1, enthalpy of 
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activation, ∆H≠ = 19.0 kJ mol-1 and free energy of activation as ∆G≠ = 78.8 kJ mol-1. 
These parameters are indicative of an associative mechanism. 
 
 
Figure 6-10a: Temperature dependence of cysteine-NAMI-A reaction. Increase in rate 
observed with temperature increase. [Cysteine]o = 5.0 x 10-2M; [NAMI-A]o = 1.0 x 10-
4M; Temp = (a) 10o C (b) 15o C (c) 20o C (d) 25o C (e) 37o C  
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Figure 6-10b: Arrhenius plot extracted from study of effect of temperature (Figure 5-
8a) for determination of activation parameters. 
 
6.3 Μechanism 
6.3.1 Electron Transfer: Considering the pKas for cysteine ionization,221 a solution 
buffered at pH 7.4 will have cysteine ionized as represented in R2 and R3 where 
H2OC(NH2)CHCH2SH is cysteine. Some thiolate form will also exist in solution 
although in low concentration compared to the zwitter ionic form as represented by R4.  
 
HOC$NH%CHCHSH    º   O  C$NH%CHCHSH     	    H                  K       R2 
 O  C$NH%CHCHSH  	     H   º      O  C$ N  H%CHCHSH                K         R3 
1/T (K-1)
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 O  C$ N  H%CHCHSH     º   O  C$ N  H%CHCHS      	      H             K       R4 
 
Zwitter ionic cysteine is expected to be the predominant species in solution. All of the 
different cysteine forms will react with NAMI-A to form products through a more 
ordered transition state, see R5 – R10. 
 
O  C$NH%CHCHSH   	   ImRuClDMSO   
                                O  C$NH%CHCHSH. . . ImRuClDMSO                    k          R5    
 
O  C$ N  H%CHCHSH  	   ImRuClDMSO   
                           O  C$ N  H%CHCHSH. . . ImRuClDMSO                       k           R6    
 
O  C$ N  H%CHCHS   	  ImRuClDMSO   
                             O  C$ N  H%CHCHS. . . ImRuClDMSO                        k         R7    
 
2 O  C$NH%CHCHSH. . . ImRuClDMSO   
HOC$NH%CHCHSSCHCH$NH%COH 	 2ImRuClDMSO               k            R8  
 
2 O  C$ N  H%CHCHSH. . . ImRuClDMSO    
HOC$NH%CHCHSSCHCH$NH%COH   	  2ImRuClDMSO 	  2H      kB   R9  
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2 O  C$ N  H%CHCHS. . . ImRuClDMSO    
HOC$NH%CHCHSSCHCH$NH%COH   	   2ImRuClDMSO                 kD   R10  
 
Describing the reaction rate, υ, in terms of disappearance of NAMI-A;  
 
 υ -  ImRuClDMSO$k O  C$NH%CHCHSH 	  k O  C$ N  H%CHCHSH 	
                                                         k3 −O2C 	NH3CHCH2S−                                             E1    
 
Results obtained from ionic strength effects demonstrate that species of similar charges 
are involved in the rate limiting step, thus indicating that k2, involving the zwitter ionic 
cysteine does not contribute significantly to the rate (k2 >> k1, k3).  Including k2 anyway, 
results in a rate that is linearly dependent on [H+] which contradicts observation of 
reduced rate at lower pH. E1, therefore, reduces to  
 
υ - ImRuClDMSO$2 O  C$NH%CHCHSH 	  2 O  C$ N  H%CHCHS     E2 
 
E2 can be expressed in terms of initial cysteine concentration, [H2OC(NH2)CHCH2SH]o 
which is distributed between [-O2C(NH2)CHCH2SH], [-O2C(+NH3)CHCH2SH]  and [-
O2C(+NH3)CHCH2S-];  
 
  υ    - HOC$NH%CHCHSH /ImRuClDMSO   F 012H 	 010G2H                 E3 
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which in conditions of overwhelming excess of MESNA can be written as  
 
                             Rate     -       27ImRuClDMSO                                                             E4 
where  
 
     27        -    HOC$NH%CHCHSH /  F 012H 	  010G2H                                     E5 
 
6.3.2 Ligand Exchange: Series of ligand substitution reactions are expected to occur 
especially following formation of the labile NAMI-A dianion, [ImRuCl4dmso]2-. 
Reactions R11 and R12 describe ligand exchange for supported by ESI-MS results 
(Figures 6-4a and b) for the loss of imidazole and dimethyl sulfoxide ligands with 
exchange of two chloride ligands.  
 
ImRuClDMSO  	   2HO   ImRuCl$HO%DMSO   	   2Cl                        R11 
ImRuCl$HO%DMSO                RuCl$HO%    	  Im   	   DMSO                  R12 
 
Greater reactivity of [ImRuCl4dmso]2- is an indication that R11 and R12 are fast and 
would not influence the rate determining step. The overall reaction is summarized in 
Figure 6-11. H, [RuCl2(H2O)2], attempts structural arrangement of the aquated product. 
Substitution could be on any two of the Cl- ligands, depending on activation enthalpy 
and free energy of the different configurations. Higher calculated energy values have 
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been reported for second aquation step of NAMI-A leading to a trans configuration. 
279;280
 
 
 
Scheme 6-1: Proposed mechanism for the reduction of NAMI-A by cysteine and 
subsequent hydrolysis. 
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Orders of magnitude lower rate constants than obtained in this study have been reported 
for experimental and theoretical hydrolysis of NAMI-A.245 281;282 This is in support of 
our proposed formation of aquated product through reduced NAMI-A. 
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CHAPTER SEVEN 
7.0 Summary and Conclusions 
Decline in cancer mortality rates acknowledges improvements and advances in 
cancer treatment. For instance, surgical removal of primary tumors is becoming highly 
successful, however, afore-mentioned characteristics of metastasis warrant 
chemotherapy. Lack of effective therapeutics towards metastasis adequately maintain 
interest in drug candidates with antimetastatic potential such as NAMI-A. Studies of 
interactions of NAMI-A with bio-relevant molecules are of considerable interest due to 
the promising pharmacological benefits of this experimental drug in cancer therapy.  
Solution chemistry of NAMI-A is quite interesting and this study has 
demonstrated that its interaction with biologically-relevant thiols can be as interesting 
and complex especially past the electron transfer process. Stoichiometry for the overall 
electron transfer reactions obtained in this study demonstrates a 1:1 ratio of oxidant to 
reductant which culminates in ligand exchange with water as described in chapters 3, 4 
and 6. Initial reactions were centered on sulfur atoms of thiols investigated, there was 
no evidence for interactions on the nitrogen or oxygen atoms. In all cases, reactions 
were dependent on NAMI-A to the first order. There was no clear evidence for binding 
of thiol to NAMI-A or any of the aquated species observed, though, our results 
demonstrate complex interactions with respect to cysteamine and GSH. Formation and 
identification of such species could be determined using time dependent NMR and LC-
MS. Further clarification of origin of [RuCl2(H2O) 2] species could be done using a Q-
band EPR which will show some signal for Ru3+ but would be EPR silent for Ru2+.  
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 Results of kinetics analysis of reactions of NAMI-A with select thiols yields 
effective rate constant, ko, which are reported in Table 7-1 for the purpose of 
comparison.  
Thiol Structure S-H pKa 
Pseudo first-
order rate 
constant, ko/s-1 
 
Cysteamine 
 
 
8.27a 6.85 + 0.3 x 10-1 
Cysteine 
 
8.7a 9.40 + 0.5 x 10-2 
GSH 
 
 
8.75a 7.42 + 0.4 x 10-3 
MESNA 
 
9.2b 3.63 + 0.3 x 10-2 
 
Table 7-1: Comparison of observed rate constants in relation to thiol pKa. a S-H pKa 
adapted from Handbook of Chemistry and Physics.221      b  283;284 
GSH exhibits the lowest rate determined, an explanation might be drawn from its 
molecular structure where the thiol might not be necessarily accessible due to steric 
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hindrance compared to other thiols studied. Also, the simple molecular structure of 
cysteamine might account for the observed high reactivity. This is not surprising since 
similar trends have been observed for kinetics analysis of reactions of GSH, MESNA 
and WR-1065 with metabolites of cyclophosphamide (4-hydroperoxycyclophosphamide 
and acrolein).285 4-hydroperoxycyclophosphamide and acrolein have high reactivity 
towards MESNA and GSH than NAMI-A on the basis of reported rate constants285 
which are orders of magnitude higher than those obtained in this study. A clinical 
indication of comparing our results with those obtained for 4-
hydroperoxycyclophosphamide and acrolein is that NAMI-A could not compete with 
these metabolites for the studied thiols provided rate constants are similar within and 
outside the cell.  
 A negative correlation of ko with thiol pKa was observed. Higher pKa 
corresponds to lower reaction rate with NAMI-A except for MESNA. Thiol with the 
lowest pKa should have higher amount of deprotonated sulfhydryl group (thiolate 
anion) and thus reacts faster at physiological pH 7.4. A Brønsted plot derived from data 
presented in Table 7-1 shows linearity as seen in Figure 7-1. Brønsted equation is log ko 
= -1.4pKa + 11. The plot demonstrates a positive slope when molecular weights of the 
thiols were factored in i.e. plot of log (MW/ko) vs pKa linear with positive slope. This 
correlation is indicative of significant contribution of thiolate anions of the different 
thiols in their reactivity with NAMI-A. Similar observations have been made in the 
reactions of thiols with Cytochrome c, a heme protein.286 WR-1065 has a lower pKa for 
thiol ionization of 7.7 and should have thiolate species up to 22 % at pH 7.4, one could 
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predict that WR-1065 will have a higher rate compared to cysteine, MESNA and GSH. 
In all, our results suggest that NAMI-A interactions with any of the thiols investigated 
should not interfere with the protective effect of amifostine or MESNA when used in a 
therapy regimen combining NAMI-A with any anticancer drug for which 
chemoprotection is necessary.  
 
 
Figure 7-1: Brønsted relationship for the reactivities of thiols towards NAMI-A. 
Linearity of this plot demonstrates significance of thiolate species in the reactions. 
 
 All the reactions studied show positive temperature dependence. Positive low 
enthalpy of activation and distinctly negative entropy of activation (see Table 7-2) 
pKa
8.2 8.4 8.6 8.8 9.0 9.2
lo
g 
k o
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0 Cysteamine
Cysteine
GSH
MESNA
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determined in all of the reactions are indicative of organized transition state prior to 
product formation.  
 
 
Thiol       ∆S≠ / JK-1mol-1     ∆H≠ / kJmol-1   ∆G≠ / kJmol-1 
Cysteamine   -117   +41   +76 
Cysteine   -200   +19   +79 
MESNA   -175   +21   +73 
GSH    -100   +55   +85
 
 
Table 7-2: Activation parameters (at 25 oC) deduced from Arrhenius plot of Ln ko 
against 1/T for thiols studied. 
 
Order of increasing free energy of activation of NAMI-A reaction with thiols in this 
study is MESNA < cysteamine < cysteine < GSH. This might explain the low rate 
constant obtained for GSH reaction. Higher than expected ko, of 3.63 + 0.3 x 10-2 s-1 
obtained for the MESNA reaction (refer to Table 7-1) in comparison to others might be 
due to occupation of a lower energy space by its transition state complex.   
 Our results could help to understand the mechanism of interaction of NAMI-A 
with cellular thiols, proteins and enzymes containing cysteine residues in their active 
sites and thiol containing chemoprotectants. Antimetastatic effects of NAMI-A appear 
independent of route of administration but dependent on amount administered.287 Mode 
of drug administration determines possible first contact. Intravenous NAMI-A 
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administration suggests interactions with biomolecules (especially in the plasma) might 
occur before interaction with DNA or other cellular targets yet to be identified and may 
proceed through similar mechanisms as those derived in this study. The use of MESNA 
should be particularly advantageous as interactions which precede ligand substitution 
should produce a more effective chemoprotectant, dimeric MESNA. The GSH-NAMI-
A reaction is relatively slow compared to other thiols studied which might suggest 
minimal impact on cellular GSH especially in the presence of other cancer drugs which 
deplete GSH.  
Reports attest to preferential binding of HSA to reduced NAMI-A,288 and 
reduced antimetastatic activity of NAMI-A upon binding to albumin and transferrin.93 
Table 7-2 features results in literature of experimental and theoretical calculations for 
physiologically relevant interactions of NAMI-A.  
 
   ko/s-1          ∆H≠ / kJmol-1  ∆G≠ / kJmol-1  Ref. 
Aquation  2.56 x 10-4*a  -  -   281 
   5.17 x 10-4*b  -  -   289 
 1st  3.96 x 10-6#  +101.5# +103.7#  279 
 2nd  -   +118.7# +125.0#  279 
Transferrin   1.07 x 10-3*b  -  -   289 
Albumin  2.77 x 10-3*b  -  -   289 
 
Table 7-3: Observed rate constants and activation parameters reported by others for 
first/second aquation processes, transferrin and albumin binding constants. * Phosphate 
buffer pH 7.4,  a at 25 oC,  b at 37 oC,   #  from density functional theory calculations.  
117 
 
Results reported in this dissertation demonstrate that interactions of NAMI-A with 
biologically-active thiols are kinetically and thermodynamically favored and therefore 
might play significant roles in in vivo metabolism of NAMI-A.  
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CHAPTER EIGHT: SUPPLEMENTARY RESULTS 
 
8.0 Kinetics and Mechanism of One-electron Oxidation of L-Cysteine by 
 Tris(1,10-phenanthroline)iron(III) complex 
8.1 Introduction: L-cysteine is the only sulfur contributor and the rate-limiting 
substrate in the biosynthesis of GSH.290 1,10-Phenanthroline ligand disturbs the proper 
functioning of a wide range of biological systems. In its metal-free state, it has been 
shown to have high inhibitory activity against candida albicaans and induced apoptosis 
in a yeast and mammalian cell line obtained from poorly differentiated carcinoma when 
complexed with metals.291;292Metal complexes are used to model biomolecules293;294 and 
iron complexes in particular, have been used to model iron-porphyrin proteins295;296 and 
active site of ribonucleotide reductase.297 Some metal complexes of substituted 1,10-
phenathroline have also shown antineoplastic activity with up to 50% growth inhibition 
of human cancer cells at concentrations of 10 to 100 times lower than cisplatin.298 
Structure-activity relationships have been established for metal complexes with 
anticancer activities.289 In this study, tris(1,10-phenanthroline)iron(III) (see structure 
shown in Figure 8-1) is used as a model that offers a familiar metal to the physiological 
system and the octahedral structure of the antimetastatic prodrug of interest in an effort 
to establish mechanisms of interactions of the prodrug with biologically-active thiols. 
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Figure 8-1 : Tris(1,10-phenanthroline)iron(III)  
 
8.2 Materials  
L-cysteine, sodium perchlorate (NaClO4) and 1,10-phenanthroline monohydrate 
all with 99+% assays were purchased from Acros. Chlorine gas (Aldrich), sulfuric acid, 
perchloric acid (Fisher) and ferrous ammonium sulfate (Fe(NH4)2(SO4)2  (GFS) were all 
used without further purification. Solutions were prepared in distilled deionized water 
obtained from a Barnstead Corporation Nanopure water system. 
Tris(1,10-phenanthroline)iron(III) perchlorate was prepared according to a 
published method.299 A solution containing 0.3 g of Fe(NH4)2(SO4)2.6H2O  (0.76 
mmol), 0.6 g of 1,10-phenanthroline monohydrate and 0.2 mL of concentrated H2SO4 in 
100 mL of water affords tris(1,10-phenathroline)iron(II) perchlorate. The iron(III) 
complex was prepared by oxidation of the iron(II) complex with chlorine gas. Chlorine 
gas was bubbled into this solution until the color changed from deep red to blue. 30% 
NaClO4 was added to the mixture and then cooled in ice bath. Blue crystalline 
Fe(phen)3(ClO4)3 was isolated by filtration and washed 3x with cold water. It was then 
dried in a desiccator. The blue iron(III) complex was recrystallized from aqueous 
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perchlorate solution and characterized spectrophotometrically. Stock solutions of the 
iron(III) complexes were freshly made in 2.0 M H2SO4. 
 
8.3 Results and discussion 
8.3.1 Stoichiometry and product identification 
The stoichiometry of the reaction was found to be 1:1 with one mole of cysteine 
reacting with one mole of tris(1,10-phenanthroline)iron(III), Fe(phen)33+, to form 
cystine (disulfide of cysteine) and tris(1,10-phenanthroline)iron(II), Fe(phen)32+, as 
shown in stoichiometric reaction R1: 
 
2RSH    +    2Fe(phen)33+                          RSSR     +     2Fe(phen)32+     +     2H+ R1 
 
Figure 3.3 shows the spectral changes observed from a solution of cysteine and 
Fe(phen)33+ scanned at 30 second intervals. The absorbance at 350 nm (λmax for 
Fe(phen)33+) decreased as the reaction progressed showing conversion of Fe(phen)33+ to 
Fe(phen)32+. The absorption at 510 nm increases as the reaction progressed to a final 
absorbance at completion of reaction. The absorbance at 510 nm corresponds to 
Fe(phen)32+ produced. The characteristic absorption at 510 nm of Fe(phen)32+ as shown 
in Figure 8-2 gives spectrophotometric evidence for our product. The observation of an 
isobestic point suggests there are no intermediates of kinetic significance during this 
oxidation and the only absorbing species in this region are Fe(phen)32+ and Fe(phen)32+. 
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Figure 8-2: Rapid spectral scan of solution of cysteine and Fe(phen)33+ taken at 30 s 
interval. [Cysteine]o = 2.0 x 10-5 M; [Fe(phen)33+]o = 5.0 x 10-5 M; [H+]o = 0.5 M 
 
 A full electro-spray ionization mass spectrum of stoichiometric solution was 
taken in the positive mode (Figure 8-3), showing m/z 241 and 298 for cysteine and 
Fe(phen)32+ respectively. The observed peak for Fe(phen)32+ is [M+H]+, taking into 
account the molecular weight of 596.27 g/mol and the +2 charge. 
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Figure 8-3:  Positive ESI-MS spectrum of the reaction products of a stoichiometric 
solution of cysteine and Fe(phen)33+  in 50/50 methanol-water. 
 
8.3.2 Effect of [Fe(phen)33+] on rate of reaction 
Kinetics of reaction were carried out under pseudo-first order conditions of 
excess cysteine. At constant temperature, ionic strength and concentration of cysteine as 
well as initial acid concentrations, effect of Fe(phen)33+ on rate of reaction was isolated 
at its wavelength of maximum absorption, 350 nm (see Figure 8-4a.). The rate of 
consumption of Fe(phen)33+ increases with increasing initial Fe(phen)33+ concentrations. 
The plot of initial rate against initial Fe(phen)33+ concentrations is linear, Figure 8-4b; 
clearly suggesting a first-order dependence in Fe(phen)33+.  
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Figure 8-4a:  Kinetic traces showing the on Fe(phen)
10-3M; [H+]o = 0.5 M; [Fe(phen)
M (d) 6.0 x 10-5 M  (e) 7.0 x 10
 
Fe(phen)32+ has maximum absorption at 510 nm, 
concentrations of Fe(phen)
(Figure 8-4c). The rate of formation of 
Fe(phen)33+ concentrations. 
concentration gave a straight line with intercept 
This affirms the results obtained at 350 nm observation wavelength. A pseudo
order rate constant of 1.43 x 10
3
3+ 
at its λmax. [Cys
3
3+]o = (a) 3.0 x 10-5 M (b) 4.0 x 10-5 M (c) 5.0 x 10
-5 M (f) 8.0 x 10-5 M (g) 9.0 x 10-5 M 
and the effect of varying initial 
3
2+
 on the reaction was also examined at this wavelength
Fe(phen)32+ increased with increasing initial 
The plot of initial rates against initial
kinetically indistinguishable from zero. 
-2
 s-1 was deduced. 
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Figure 8-4b: Initial rate plot derived from Figure 8-4a, showing linear dependence on 
Fe(phen)33+.  
 
       
Figure 8-4c: Effect of [Fe(phen)3 3+] variation on the formation of Fe(phen)3 2+ at 510 
nm. [Cysteine]o = 2.0 x 10-3 M; [H+]o = 0.5 M; [Fe(phen)3 3+]o = (a) 1.0 x 10-5 M 
through (h) 8.0 x 10-5 M 
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8.3.3 Effect of cysteine on reaction rate: The effect of cysteine on its oxidation by 
Fe(phen)3 3+ was monitored at 350 nm and 510 nm Figure 8-5, summarizes this effect. 
The rate of consumption of Fe(phen)3 3+ (dashed lines) increased with increased 
concentrations of cysteine. The same trend was observed when monitoring the rate of 
formation of Fe(phen)32+ at 510 nm (solid lines). Initial rate plots deduced from Figure 
S-5 show linear-order dependence but with saturation. 
 
 
 
 
 
 
 
 
 
Figure 8-5: The dashed lines show consumption of the oxidant, Fe(phen)3 3+ at 350 
nm and the solid lines show formation of Fe(phen)32+ at 510 nm. In both cases rate was 
increased with cysteine.  
 
8.3.4 Effect of acid on reaction rate: While other reaction conditions were kept 
constant, the dependence of reaction on initial acid concentrations was evaluated. 
Figure 8-6 summarizes the effect of acid variation on both the rate of consumption of 
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oxidant at 350 nm and the rate of formation of the reduced complex at 510 nm. The 
range of possible variations with respect to initial acid concentrations is limited since 
the stock Fe(phen)33+ solution was made in 2.0 M acid. This was to prevent the aquation 
of  Fe(phen)33+ into the undetermined khaki colored polymeric hydroxo complexes.300 
The observation is that acid has an inhibitory effect on the reaction as the rate of 
product formation decreases with increase in acid concentrations. Both initial rates 
show inverse acid dependence. 
 
    
 
 
 
 
 
 
 
Figure 8-6: Evaluation of effect of initial acid concentrations. An inverse acid 
dependence observed on the rate of formation Fe(phen)32+ (510 nm)  and consumption 
of Fe(phen)33+ (350 )nm.  [Fe(phen)33+]o = 5.0 x 10-3 M; [Cysteine]o =5.0 x 10-3 M; 
[H+]o = (a) 0.30 M; (b) 0.40 M; (c) 0.50 M; (d) 0.60 M.  
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8.3.5 Effect of ionic strength: The response of the present reaction to changes in 
concentration of an inert salt, at constant temperature and reactants concentrations, was 
examined (Figure 8-7). Increasing ionic strength decreased the rate of reaction. This 
might suggest that the rate determining step(s) contain species of different charges. 
 
 
 Figure 8-7: Evaluation of effect of ionic strength. [Cysteine]o = 2.0 x 10-3M; 
[Fe(phen)33+]o = 5.0 x 10-5 M; [H+]o = 0.5 M; [µ]NaClO4 = (a) 0.4 M (b) 0.6 M (c) 0.8 M 
(d) 1.0 M (e) 1.2 M (f) 1.4 M (g) 1.6 M (h) 1.8 M (i) 2.0 M. 
  
8.3.6 Thermodynamic and activation parameters: At constant ionic strength, acid 
and concentrations of oxidant and substrate, the effect of temperature on the reaction 
was evaluated. Reaction rate increased proportionally with increasing temperatures as 
expected (see Figure 8-8a). The obtained kinetics data were used to construct an 
Arrhenius plot (see Figure 8-8b).  
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Figure 8-8a: Temperature dependence of cysteine-ferriin reaction. Increase in rate 
observed with temperature increase. [Cysteine]o = 2.0 x 10-3M; [Fe(phen)33+]o = 5.0 x 
10-5M; [H+]o = 0.5 M; Temperature in increament of 5 oC from 10 through 30 oC. 
 
 
Figure 8-8b: Arrhenius plot extracted from study of effect of temperature variation on 
the reaction for determination of activation parameters. 
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 The Arrhenius plot afforded these activation parameters: entropy of activation, 
∆S≠
 
= -217.02 + 0.03 J K-1 mol-1, enthalpy of activation, ∆H≠ = 35.85 + 0.38 kJ mol-1 
and free energy of activation as ∆G≠ = 100.52 kJ mol-1. The distinctly negative entropy 
of activation suggests some degree of molecular ordering in the rate determining step. 
This is indicative of an associative mechanism. 
 
8.3.7 Mechanism  
The results obtained have allowed us to propose stepwise reactions involved in 
the oxidation of L-cysteine by Fe(phen)33+. Reactions were carried out in acidic 
medium, therefore, cysteine (RSH) exists mostly in the protonated form as shown in R2. 
 
 
 
Unprotonated cysteine also exists but to a lesser extent in the reaction. Both protonated 
and unprotonated cysteine can react with Fe(phen)33+ to associative complex (R3 and 
R4). This is supported by the thermodynamic parameters obtained from Figures 8-8a 
and b. The activated complexes formed in R3 and R4 then proceed to form products as 
shown in R5. Contribution from intermediate complex formed by R4 would be minimal 
since unprotonated cysteine concentrations are negligible 
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Following the disappearance of Fe(phen)33+ the rate of reaction can be written as: 
 
-d[Fe(phen)33+]       =      k1[Fe(phen)33+][RSH]       +       k2[Fe(phen)33+][RSH2+]
         dt
 
From R2, the concentration of protonated cysteine can be written as 
 
[RSH2+]     =     Kb[RSH][H+]
        
  
The concentrations of all cysteine species are derived from initial cysteine 
concentration, therefore, 
 
[RSH]o    =       [RSH]      +     [RSH2+]   
     
Substituting for [RSH2+] in equation 
 
[RSH]    =     [RSH]o   
                     1 + Kb[H+]
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The rate then becomes: 
 
 
 
 There is a first-order dependence on Fe(phen)33+  and cysteine as demonstrated 
by Figures 8-4a – c and Figure 8-5 respectively. This rate shows a complex dependence 
on acid concentration. Figure 8-6 demonstrates inhibitory effect of acid on the reaction. 
At low acid concentrations, rate would be first-order in acid but in high acid 
concentrations, however, the reaction saturates as observed in Figure 8-6. An 
explanation for retardation by acid is that high acid concentration increasingly stabilizes 
Fe(phen)33+, making it react more slowly. The rate law can then be simplified to 
 
Rate   =    ko[RSH]o[Fe(phen)33+]
  
where  
 
 
 The bimolecular rate constant for the reaction was 7.15 M-1s-1. The 
thermodynamic parameters obtained indicate formation of associative intermediate prior 
to product formation. Saturation in cysteine dependence can may be due to sequestering 
132 
 
of cysteine by Fe(phen)33+  to form an initial complex which does not contribute 
significantly to the product. 
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